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Abstract 
The purpose of this thesis was to test the hypothesis that changes in circulating sex 
hormone levels are associated with changes in muscle sympathetic nerve activity. The 
hypothesis was tested through the comparison of low- (early follicular [EF]) and high-
hormone (midluteal [ML]) phases of the menstrual cycle and of hormonal contraceptive use 
(low hormone [LH] versus high hormone [HH]). The microneurography technique was used 
to compare both the frequency and size of bursts in muscle sympathetic nerve activity 
(MSNA) at baseline and during two sympatho-excitatory maneuvers: baroreceptor unloading 
elicited through lower body negative pressure, and chemoreflex stimulation elicited through a 
hypoxic-hypercapnic end-inspiratory apnea. Sympathetic responses to chemoreflex 
stimulation were also compared between women and men. All associations between MSNA 
and hormone phases occurred similarly between users and non-users of hormonal 
contraceptives. At baseline, MSNA was relatively elevated during the high hormone phases 
(ML and HH), at which point baseline sympathetic activity was similar to that observed in 
men. However, stimulation of the chemoreflex resulted in greater sympathetic activation 
during the low hormone phases (EF and LH) relative to the high hormone phases. Further, 
this hormone phase effect was mediated largely by greater increases in burst size, rather than 
the burst frequency component. This may indicate that central integration sites for MSNA are 
affected by circulating sex hormone levels. Finally, the sympathetic responses to 
baroreceptor unloading were graded to reductions in stroke volume, which, in turn, were 
affected by hormone levels. However, no evidence was observed to suggest a change in the 
central integration of baroreceptor afferent input occurred across phases of the menstrual 
cycle or hormonal contraceptive use in terms of baroreflex function. Together, these studies 
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confirm that sympathetic nerve activity at baseline and sympathetic recruitment during 
chemoreflex stimulation are affected by hormone phase, while baroreceptor-mediated 
responses are not affected by the transition from low (EF and LH) to high hormone phases 
(ML and HH).  
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Chapter 1  
1 Introduction 
1.1 Overview 
Cardiovascular disease risk is reduced in premenopausal women relative to age-
matched men (Rosenthal & Oparil, 2000;Young et al., 1993;Eaker et al., 1989) (Figure 
1.1, for example). Following menopause, this relative cardioprotection is lost such that 
cardiovascular disease risk is increased significantly in post-menopausal women (Rosano 
et al., 2007). The sympathetic nervous system has been implicated as a contributor to the 
loss of premenopausal cardioprotection based on its importance in the control of 
cardiovascular function (Wallin & Charkoudian, 2007) and the positive associations 
which exist between heightened sympathetic nerve activity and incidence of 
cardiovascular disease (Leimbach, Jr. et al., 1986;Yamada et al., 1989;Miyajima et al., 
1991;Carlson et al., 1993). Accordingly, examinations of baseline conditions have 
indicated that sympathetic nerve activity is elevated in men compared to pre-menopausal 
women (Ng et al., 1993;Matsukawa et al., 1998;Narkiewicz et al., 2005). Moreover, 
sympathetic nerve activity increases following menopause, matching or exceeding levels 
observed in similarly aged men (Matsukawa et al., 1998;Narkiewicz et al., 2005) (Figure 
1.2). Together, the similar patterns of sex- and age-related changes in sympathetic nerve 
activity and cardiovascular disease support a possible role for the sympathetic nervous 
system in the reduced incidence of cardiovascular morbidity in premenopausal women. 
However, the source of the relative sympatho-inhibition in premenopausal women is less 
clear. 
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Figure 1.1: Prevalence of hypertension in men and women. 
Hypertension is more prevalent in young men than young women, but this sex difference 
disappears following menopause. Reproduced with permission from Nature Publishing 
Group: Journal of Human Hypertension (Rosenthal & Oparil, 2000). 
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MSNA is lower in young women than in age-matched men. In middle aged and older 
adults, MSNA is similar or greater in women than in men. Adapted with permission from 
Lippincott Williams and Wilkins/Wolters Kluwer Health: Hypertension (Narkiewicz et 
al., 2005).  
Figure 1.2: Baseline sympathetic nerve activity in men and women 
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Circulating concentrations of estrogen and progesterone are elevated in women 
relative to men and are dramatically reduced in women following menopause (Conte & 
Grumbach, 2007). Together with the data summarized above, this suggests that sex 
hormones may affect sympathetic regulation in women with important cardiovascular 
consequences. Further support for this hypothesis has come from women with polycystic 
ovary syndrome. In these women, levels of circulating testosterone and baseline 
sympathetic nerve activity are elevated relative to control subjects (Sverrisdottir et al., 
2008). However, both the polycystic ovary syndrome and post-menopausal conditions 
represent alterations to the normal hormonal milieu which is observed in healthy young 
premenopausal women. The concept that sex hormones exert an influence over levels of 
sympathetic nerve activity and potentially contribute to the  high degree of interindividual 
variability in baseline sympathetic nervous system activity which is observed in young 
healthy subjects (Joyner et al., 2010;Wallin, 2006) has only been examined relatively 
recently.  
The sympathetic effects of "normal" fluctuations in hormone levels have been 
examined through the study of the menstrual cycle, which is associated with large 
endogenous fluctuations in circulating estrogen and progesterone. Several such studies 
have observed relative increases in baseline sympathetic nerve activity during the 
menstrual cycle phase associated with heightened levels of both estrogen and 
progesterone, the midluteal phase, in comparison to the early follicular phase which is 
associated with low levels of estrogen and progesterone (Minson et al., 2000a;Park & 
Middlekauff, 2009;Middlekauff et al., 2012;Carter et al., 2013). While these data support 
a possible link between sex hormones and sympathetic regulation in young healthy 
5 
 
women, it is important to consider that an almost equal number of studies have failed to 
observe the same effect (Carter et al., 2009b;Fu et al., 2009;Carter & Lawrence, 2007). 
The lack of ubiquity in these results might imply that the association between 
sympathetic nerve activity and menstrual cycle phase is a mild one. It is also possible that 
this association is strengthened during sympatho-excitation: studies of sympathetic 
responses to the sympatho-excitatory stress of baroreceptor unloading have consistently 
observed greater sympathetic nerve activity in the midluteal phase of the menstrual cycle 
than during the early follicular phase (Fu et al., 2009;Carter et al., 2009b). Also, the 
differences in sympathetic activity between menstrual cycle phase appear to be most 
pronounced during the most severe phases of baroreceptor unloading (Fu et al., 
2009;Carter et al., 2009b). Therefore, one purpose of these studies was to assess whether 
menstrual cycle-driven fluctuations in hormone levels affect sympathetic outflow during 
states of high reflex stress. To achieve this objective, sympathetic regulation across the 
menstrual cycle was measured during baroreceptor unloading evoked using high levels of 
lower body negative pressure and during chemoreflex activation which is known to be 
associated with large increases in sympathetic nerve activity (Morgan et al., 1995;Saito et 
al., 1988).  
A notable addendum to this field of research is the consideration of women whose 
endogenous fluctuations of sex hormones are impeded and supplemented by synthetic, 
exogenous hormones. This is an important issue given that at least 20% of women of 
child-bearing age currently use hormonal contraceptives (Mosher & Jones, 2010) which 
alter the types and profile of monthly variations in hormones levels. The influence of 
hormonal contraceptive use on sympathetic regulation has become the focus of a few 
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recent studies which have targeted similar hormone phases as those studied across the 
menstrual cycle (specifically, the low-hormone, inactive phase of contraceptive use 
versus the high-hormone, active phase) (Minson et al., 2000b;Carter et al., 
2009a;Middlekauff et al., 2012). However, the effects of hormonal contraceptive use on 
sympathetic regulation have been under-studied relative to menstrual cycle studies, and to 
date only one study has directly compared the two (Middlekauff et al., 2012). Therefore, 
another purpose of these studies was to establish the effects of hormonal contraceptive 
use on sympathetic regulation patterns.  
The overall objective of this research is to understand the effects of sex hormones 
on sympathetic nerve activity by comparing the responses to sympatho-excitatory 
maneuvers during the low and high hormone phases of the menstrual cycle and of 
hormonal contraceptive use. The working hypothesis of these studies is that hormone 
phase affects sympathetic nerve activity particularly during reflex activation. This, in 
turn, affects the observation of male-female differences in sympathetic regulation.  
Study 1. Hormone phase influences neurovascular responses to high levels of lower 
body negative pressure. 
Purpose: To compare MSNA responses to moderate to high levels of lower body 
negative pressure between low- and high-hormone phases of both the regular 
menstrual cycle and hormonal contraceptive use. 
Hypothesis: Hormone phase (regardless of group) would affect sympathetic 
responses such that in both groups of women the higher hormone phases would be 
associated with greater sympathetic responses than the lower hormone phases.  
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Study 2. Hormone phase dependency of neural responses to chemoreflex-driven 
sympatho-excitation in young women using hormonal contraceptives.  
Purpose: To compare muscle sympathetic nerve activation patterns between low 
and high hormone phases of exogenous contraceptive hormone use across a range 
of chemoreflexive stimuli. 
Hypothesis: Baseline and reflex sympathetic nerve activation would be greater in 
the high hormone phase relative to the low hormone phase of hormonal 
contraceptive use. 
Study 3. Sex and menstrual cycle effects on sympathetic responses to chemoreflex 
stimulation.  
Purposes: (1) To compare sympathetic responses between men and women 
during a severe chemoreflex stress, and (2) to determine whether the menstrual 
cycle is associated with changes in chemoreflex-driven sympatho-excitation. 
Hypotheses: (1) Acute hypercapnia-hypoxia would be associated with greater 
increases in sympathetic activity in young healthy women relative to men; (2) the 
low hormone phase of the menstrual cycle would be associated with greater 
increases in sympathetic activity than the high hormone phase. 
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1.2 Muscle Sympathetic Nerve Activity 
 The study of the activity of the sympathetic nervous system was greatly advanced 
by the development of the microneurographic technique by Hagbarth and Vallbo in the 
late 1960s (Hagbarth & Vallbo, 1968). In this technique, a recording electrode is inserted 
into a nerve and advanced in close proximity to efferent sympathetic nerve fibres which 
innervate the vasculature of peripheral muscles. Microneurography allows for the direct, 
real-time recording of muscle sympathetic nerve activity (MSNA) which has paved the 
way for decades of studies detailing sympathetic regulation mechanisms. 
 The microneurography technique involves the use of two tungsten electrodes, one 
of which is inserted percutaneously 1-3 cm from the active recording site and serves as 
reference electrode. The other is the recording electrode and is inserted transcutanously, 
commonly into the peroneal nerve. This nerve is ideal for the study of MSNA as it is 
easily accessible, relatively large, and contains a large number of efferent sympathetic 
neurons (Tompkins et al., 2013). As described by Delius and colleagues, adequate 
MSNA recording sites are determined through the observation of several criteria (Delius 
et al., 1972). The MSNA signal produces pulse synchronous bursts of activity which 
increase in frequency during apnea and are unaffected by arousal to a loud noise or light 
brushing of the skin (rather, these last two criteria are characteristic of skin sympathetic 
neurons). Signal processing methods are then used to amplify (e.g., 75 000x), filter 
(bandpass: 700-2000 Hz), rectify, and integrate (0.1s time constant) the raw sympathetic 
signal, producing the characteristic bursts of activity which are initiated during diastole 
(Figure 1.3). 
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Figure 1.3: Analysis of the muscle sympathetic nerve activity signal. 
Bursts of activity which are initiated during diastole are clearly visible following signal 
processing.  
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A total quantification of the integrated MSNA signal consists of two components 
which appear to be regulated differently: burst frequency and burst size, often referred to 
as burst amplitude. The firing frequency is expressed as either burst frequency or burst 
incidence.  Burst frequency is expressed in bursts per minute, while burst incidence 
involves a normalization of burst frequency to heart rate and is expressed as bursts per 
hundred heart beats. In this way, burst incidence reflects baroreceptor processing of 
efferent MSNA.  
While the methods used to quantify the frequency component of the integrated 
MSNA signal are widely accepted and reproducible over time (Sundlof & Wallin, 
1977;Kimmerly et al., 2004), the quantification of the amplitude component is more 
complicated. The complication lies in the meaning of the absolute amplitude signal and 
its implications for interindividual comparisons. Absolute burst amplitude, expressed as a 
voltage, is an indication of the number (Ninomiya et al., 1993) and size (Steinback et al., 
2010b) of neurons within the recording range of the electrode and is affected by electrode 
position. In the absence of a change in recording site, changes in burst amplitude can be 
interpreted to indicate alterations in the central regulation of MSNA burst amplitude. On 
the other hand, the extent to which the regulation of burst amplitude differs between 
subjects cannot be derived from measures of absolute burst voltages. Sverrisdottir and 
colleagues have used a method of normalization which allows for interindividual burst 
amplitude comparisons which isolates the burst amplitude component of MSNA from the 
burst frequency component (Sverrisdottir et al., 2000). This method of burst amplitude 
analysis involves the normalization of all baseline bursts to a given burst (for example, 
the largest burst in the baseline period). The normalized burst amplitudes are then divided 
11 
 
into bins, and the frequency with which each bin occurs is graphed. The statistical 
characteristics of these distribution curves can then be compared between subjects in 
terms of mean, median, and/or modes. Similar to burst frequency measures, this method 
of determining burst amplitude has been shown to be reproducible between test dates 
(Kimmerly et al., 2004).  
Twenty years ago, Malpas and colleagues put forward the hypothesis that the 
frequency of sympathetic bursts is controlled independently from the number of active 
sympathetic fibres within a given burst of activity (Malpas, 1995). Several experiments 
have provided support for this hypothesis (Malpas & Ninomiya, 1992b;Malpas & 
Ninomiya, 1992a;Sverrisdottir et al., 2000), including observations of altered 
sympathetic burst amplitude in the presence of unchanged burst frequency during mental 
stress (Hjemdahl et al., 1989), hypoxic stimulation (Malpas et al., 1996), local heating 
(DiBona & Jones, 1998), and baroreceptor stimulation (DiBona et al., 1997). A 
hypothetical model by which sympathetic burst amplitude and frequency are regulated 
independently stipulates that a variety of afferent inputs converge on unknown central 
sites of sympathetic integration to cause graded activation of sympathetic efferent 
pathways (i.e. the control of burst amplitude). Baroreceptor afferent feedback is then 
thought to act as a gating mechanism to either allow or disallow a burst of efferent 
sympathetic activity (i.e. the control of burst frequency) (Kienbaum et al., 2001) (Figure 
1.4). Within the context of this model, it is conceivable that an increase in burst 
frequency could occur in conjunction with a reduction in burst amplitude (Kienbaum et 
al., 2001). Such a possibility warrants the reporting of both burst frequency and burst 
amplitude measures when examining sympathetic responsiveness.   
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Figure 1.4: Hypothetical model for arterial baroreceptor influence on sympathetic 
nerve activity.  
Baroreceptor afferent activity (left) is incorporated with other inputs to create a graded 
influence which is reflected by burst amplitude. The gating of the resultant burst strength 
is then regulated largely by the baroreceptors, affecting the frequency with which efferent 
sympathetic bursts occur. Reproduced with permission from John Wiley and Sons: 
Journal of Physiology (Kienbaum et al., 2001).   
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1.3 Sympathetic Activity during Baroreceptor Unloading 
 The orthostatic stress which arises during upright posture due to the effect of 
gravity is associated with the peripheral pooling of blood. This, in turn, can limit venous 
return and reduce cardiac output, thereby threatening the maintenance of an arterial 
pressure necessary to adequately perfuse the body with blood. Such a reduction in cardiac 
output is detected by the mechano-sensitive baroreceptors which are unloaded by the 
associated reduction in local blood pressure. The subsequent reduction in the firing rates 
of baroreceptor afferent projections to central sympathetic sites are integrated to produce 
sympatho-excitation which is graded to the level of baroreceptor unloading and evokes an 
increase in peripheral resistance in an effort to maintain mean arterial pressure (Victor & 
Leimbach, Jr., 1987;Rowell, 1993;Johnson et al., 1974) .  
 In a laboratory setting, microneurographic recordings of MSNA are difficult to 
measure during the transition from supine to standing as the movements involved can 
dislodge the recording electrode and/or necessitate the activation of postural muscles 
which confound the MSNA signal. Methods which simulate orthostasis such as head-up 
tilt and lower body negative pressure (LBNP) have been developed to allow subjects to 
maintain relaxation in the leg in which MSNA is being recorded, thus avoiding these 
issues. Lower body negative pressure also excludes the sympathetic effects of vestibular 
otolith stimulation which occur during head-up tilt (Ray, 2000;Kaufmann et al., 2002). 
During LBNP, suction is created around the lower body below the level of the iliac crests 
which draws blood into the vascular beds contained therein. This method allows for 
careful titrations of the sympathetic response as suction can be controlled with great 
precision. Applications of LBNP as low as -5 mmHg have been associated with small but 
14 
 
significant increases in MSNA with no change in mean arterial blood pressure (Victor & 
Leimbach, Jr., 1987). Progressive increases in suction are associated with graded 
increases in MSNA (Sundlof & Wallin, 1978;Victor & Leimbach, Jr., 1987) which occur 
in response to the LBNP-induced reductions in stroke volume (Figure 1.5) (Ryan et al., 
2011). Recently, Ichinose and colleagues (Ichinose et al., 2004;Ichinose et al., 2006) 
demonstrated that increases in the amplitudes and firing frequencies of sympathetic 
bursts may depend on the severity of LBNP. Their data indicate that at levels of LBNP up 
to approximately -30 mmHg, increases in total MSNA are achieved through increases in 
both firing frequencies and burst amplitudes, while at higher levels of suction increases in 
total MSNA are achieved primarily through elevations in burst amplitude (Ichinose et al., 
2006;Ichinose et al., 2004). 
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Muscle sympathetic nerve activity (MSNA) is negatively related with stroke volume 
during a progressive LBNP protocol to presyncope. Reproduced from an open access 
article under the terms of the Creative Commons Attribution Non Commercial License 
(Ryan et al., 2012). 
 
  
Figure 1.5: Relationship between sympathetic nerve activity and stroke volume 
during baroreceptor unloading. 
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1.4 Sympathetic Activity during Chemoreflex Stimulation 
 The activation of the chemoreflex is associated with a large sympatho-excitatory 
response (Morgan et al., 1995;Saito et al., 1988). Chemoreceptors are located both 
peripherally and centrally, with different sensitivities to the nature of the chemoreflex 
stress – central chemoreceptors are sensitive to circulating carbon dioxide, while 
peripheral chemoreceptors are sensitive to both oxygen and carbon dioxide (Kara et al., 
2003). Similar to the effects of baroreceptor unloading, chemoreceptor stimulation 
produces increases in MSNA which are graded to the intensity and duration of the 
chemoreflex stimulus (Smith & Muenter, 2000). Importantly, the effects of hypoxia and 
hypercapnia are additive, such that combined hypoxia-hypercapnia produces a greater 
increase in MSNA than either hypoxia or hypercapnia alone (Somers et al., 1989). 
Chemoreflex stress has also been shown to elevate both components of the sympathetic 
signal, that is, the amplitude and the firing frequency of integrated bursts (Steinback et 
al., 2009;Malpas et al., 1996). 
 Independent of chemoreflex stress, there also exists a respiratory modulation of 
sympathetic nerve activity. Muscle sympathetic nerve activity is increased during 
expiration and inhibited during inspiration (Eckberg et al., 1985;Hagbarth & Vallbo, 
1968), an effect mediated by pulmonary stretch receptors which are activated during 
inspiration (Seals et al., 1993). As a result of the sympatho-inhibitory influence of the 
lung stretch receptors, the sympathetic responses to chemoreflex stress are amplified 
during the absence of active respiration, such as during an apnea maneuver (Steinback et 
al., 2010a;Narkiewicz et al., 1999) (Figure 1.6).  Therefore, a combination of hypoxic-
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hypercapnic and apneic stress evokes very large increases in MSNA (Steinback et al., 
2010a). 
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Hypoxia was generated through breathing of a 10% oxygen gas mixture which was 
titrated to maintain isocapnia. A 10-second end-expiratory apnea immediately followed 
the 3-minute period of hypoxic breathing. The mean sympathetic response to apnea was a 
50% increase over that observed during hypoxic breathing alone. ECG, 
electrocardiogram; HR, heart rate; O2 Sat, oxygen saturation; VE, ventilation rate; MAP, 
mean arterial pressure. Adapted with permission from Lippincott Williams and 
Wilkins/Wolters Kluwer Health: Circulation (Narkiewicz et al., 1999).  
Figure 1.6: Sympathetic nerve activity during hypoxia with and without apnea. 
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1.5 Hormone Fluctuations across the Menstrual Cycle 
The primary endogenous sex hormones which have been hypothesized to affect 
sympathetic regulation are 17-β-estradiol (E2) and progesterone (Carter et al., 2013). 
Circulating concentrations of these hormones change dramatically over the menstrual 
cycle and thus provide opportunities to study the effects of nadirs and peaks of E2 and 
progesterone. In a normal 28 day menstrual cycle, the first 14 days constitute the 
follicular phase which involves the ovarian maturation of a primary oocyte, while the 
latter 14 days are referred to as the luteal phase and are associated with the preparation of 
the uterus for the possible implantation of a fertilized oocyte (Conte & Grumbach, 2007). 
The progression of these events is regulated by circulating sex hormones.  
The follicular phase begins with menstruation, which is triggered by falling blood 
plasma concentrations of progesterone and E2 (Figure 1.7). Thus, the early follicular 
phase is associated with a nadir in circulating E2 and progesterone. During the late 
follicular phase, the ovaries produce testosterone which is immediately and locally 
converted to E2 by the enzyme aromatase.  The resultant E2 circulates through the body, 
and, at the level of the hypothalamus, initiates a positive feedback loop with the ovaries 
to dramatically increase further production of E2 (Conte & Grumbach, 2007). Thus, the 
late follicular phase is associated with high levels of circulating E2 while progesterone 
levels remain low. The follicular phase ends with ovulation, during which E2 levels are 
reduced following termination of the positive feedback loop, and the oocyte is released 
for potential fertilization.  
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Adapted with permission from John Wiley and Sons: Journal of Physiology (Wenner & 
Stachenfeld, 2012).  
Figure 1.7: Plasma hormone concentrations across a regular menstrual cycle. 
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The production of sex hormones during the luteal phase is accomplished by the 
corpus luteum, a temporary endocrine organ which is formed following ovulation (Conte 
& Grumbach, 2007). The corpus luteum synthesizes and secretes E2 and progesterone 
which act to prepare the uterine wall for implantation in the event of oocyte fertilization. 
However, E2 and progesterone also enter the circulation and as such the luteal phase is 
characterized by gradual increases in E2 and progesterone which plateau mid-way 
through the luteal phase. In the event that the oocyte is not fertilized, the corpus luteum 
degenerates, resulting in reductions in E2 and progesterone which in turn trigger 
menstruation and the beginning of a new menstrual cycle. The menstrual cycle therefore 
presents naturally occurring opportunities to study different hormonal milieus.  
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1.6 Hormonal Contraceptives 
 Many different types of hormonal contraceptives exist which act to inhibit 
ovulation and therefore prevent pregnancy. Binding to the progesterone receptor is the 
main requirement for this action, but progesterone itself is expensive and difficult to 
isolate for the purpose of hormone supplementation (Conte & Grumbach, 2007). 
Researchers have, therefore, spent the past half century developing synthetic 
progesterone analogs, called progestins. In the early development of hormonal 
contraceptive pills, the inclusion of an estrogen component was found to stabilize the 
endometrium and minimize side effects associated with contraceptive use (Burkman et 
al., 2011;Conte & Grumbach, 2007). Although progestin-only contraceptives exist, their 
use is largely restricted to special circumstances, such as women who are breast-feeding 
or who have contraindications to estrogen (Conte & Grumbach, 2007). More common are 
combined hormonal contraceptives which contain both an estrogen (ethinyl estradiol) and 
a progestin component.  
 Early generations of contraceptives included high doses of ethinyl estradiol which 
exceeded 50 µg (Conte & Grumbach, 2007). However, the majority of contraceptives 
used today contain less than 35 µg of ethinyl estradiol (Burkman et al., 2011). The 
progestin content of hormonal contraceptives has also evolved over time. This evolution 
has stemmed largely from the finding that most progestins interact not only with the 
progesterone receptor, but also with the androgen receptor (Sitruk-Ware & Nath, 2013). 
This "androgenicity" was thought to adversely affect lipid profiles and glucose tolerance 
in the early generation progestins, which were derived from testosterone (Sitruk-Ware, 
2005;Conte & Grumbach, 2007). Newer progestins, which include desogestrel, 
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gestodene, and norgestimate, were improvements on the previous generation due to 
having low androgenic activity (Speroff & DeCherney, 1993). However, progesterone 
itself is known to have antiandrogenic activity which is not mimicked by these progestins 
(Sitruk-Ware, 2005). Drospirenone is a new progestin which binds to the progesterone 
receptor with the same affinity as progesterone and has antiandrogenic activity which 
may surpass endogenous progesterone (Sitruk-Ware, 2005).  
  The development of hormonal contraceptives continues today. While the 
prevention of ovulation and therefore pregnancy is well executed by current hormonal 
contraceptives, the simulation of the physiological effects of endogenous hormones has 
not yet been achieved with current synthetic hormones (Sitruk-Ware, 2005).  
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1.7 Associations between Hormone Levels and 
Sympathetic Nerve Activity 
In a relatively new field of research, studies have begun to test women at various 
phases of the menstrual cycle to examine the effects that changes in hormonal milieus 
might exert over sympathetic regulation in young healthy women. The majority of these 
studies have focused on the early follicular (EF) and midluteal (ML) phases of the 
menstrual cycle to examine the combined effects of low (i.e. EF) or high levels of E2 and 
progesterone (i.e. ML). Fewer studies have compared low (LH) and high hormone (HH) 
phases of hormonal contraceptive use.  
Baseline studies of MSNA in recumbent subjects have, for the most part, 
demonstrated elevations in MSNA burst frequency during the ML phase relative to the 
EF phase (Middlekauff et al., 2012;Park & Middlekauff, 2009;Minson et al., 2000a). 
Several studies have reported similar baseline MSNA in EF and ML phases (Fu et al., 
2009;Carter et al., 2009b;Lawrence et al., 2008), in line with the observations from 
hormonal contraceptive users, in whom no hormone phase-dependent differences in 
baseline MSNA have been observed (Minson et al., 2000b;Middlekauff et al., 
2012;Carter et al., 2009a). It is worth noting that, of the studies which also reported 
baseline vascular resistance, none have observed a difference in vascular resistance 
between phases, regardless of hormonal contraceptive use or whether a difference in 
baseline MSNA was observed (Minson et al., 2000a;Fu et al., 2009;Minson et al., 
2000b). Similarly, the majority of studies have observed similar baseline blood pressures 
between hormone phases in both users or non-users of hormonal contraceptives (Fu et al., 
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2009;Carter et al., 2009b;Minson et al., 2000a;Middlekauff et al., 2012;Carter et al., 
2009a).  
In studies of baroreceptor unloading, both LBNP and head-up tilt (HUT) have 
been used to simulate orthostasis. These studies support a divergence between users and 
non-users of hormonal contraceptives. In non-users, greater total MSNA responses to 
baroreceptor unloading have been observed in the ML phase than the EF phase during 
both HUT and LBNP (Fu et al., 2009;Carter et al., 2009b). Although HUT activates the 
vestibulosympathetic reflex (Ray, 2000;Kaufmann et al., 2002) and has the potential to 
exaggerate the observed sympathetic responses to baroreceptor unloading (Shortt & Ray, 
1997), otolith-driven sympatho-excitation appears to be similar between EF and ML 
phases (Lawrence et al., 2008). Therefore, this hormone phase effect is thought to result 
from a baroreceptor-driven mechanism alone. However, in the majority of studies, 
differences in sympathetic baroreflex sensitivity have not been observed between EF and 
ML menstrual cycle phases (Fu et al., 2009;Carter et al., 2009b;Middlekauff et al., 2012). 
The lack of a difference in sympathetic baroreflex sensitivity, which expresses the extent 
to which MSNA increases for a given fall in DBP, implies that venous return and, 
therefore, cardiac output are reduced to a greater extent in the ML phase, thereby 
necessitating a larger sympatho-excitatory response (Fu et al., 2009).  
In the only study to date which has compared sympathetic responses to simulated 
orthostasis across hormone phases in hormonal contraceptive users, increases in total 
MSNA were similar between LH and HH phases (Carter et al., 2009a). In comparisons of 
sympathetic baroreflex sensitivity, one study observed an elevation in sympathetic 
baroreflex sensitivity in the LH phase of contraceptive use compared to the HH phase 
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(Minson et al., 2000b). However, this observation has not been repeated, with subsequent 
studies reporting similar baroreflex sensitivity between hormone phases in hormonal 
contraceptive users (Middlekauff et al., 2012;Carter et al., 2009a). 
In the study by Carter and colleagues (Carter et al., 2009b), the authors noted that, 
over the range of LBNP which was applied between -5 and -40 mmHg, the menstrual 
cycle-based differences in sympathetic activation were most visible during the higher 
levels of baroreceptor unloading. A similar trend was observed in the study by Fu and 
colleagues (Fu et al., 2009), with the differences in total MSNA appearing greatest in the 
latter 20 minutes of the 45-minute HUT protocol. Therefore, it is possible that hormone 
phase may affect sympathetic responses to a greater extent during more severe reflex 
stress. Whether this effect is baroreceptor-dependent remains to be determined. These 
questions provided an impetus for this series of studies.  
Notably, two studies which have reported an effect of hormone phase on 
sympathetic activation during baroreceptor unloading have observed these effects on total 
MSNA without a concomitant effect on MSNA burst frequency (Fu et al., 2009;Carter et 
al., 2009b). As the authors note, this strongly implies that elevations in E2 and 
progesterone are associated with specific sympatho-excitatory effects in the burst 
amplitude domain of MSNA. However, due to the limitations outlined in Section 1.2, 
MSNA burst amplitude is seldom reported. Therefore another purpose of these studies 
was to explore MSNA burst amplitude in greater detail, and led to the inclusion of 
chemoreflex stimulation in these studies as a means to evoke large increases in burst 
amplitude (Steinback et al., 2009;Malpas et al., 1996). 
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While the majority of research has focused on hormone phase effects on 
baroreceptor-drive regulation of sympathetic activity, other studies have compared high 
and low hormone phases during other sources of sympatho-excitation. These results have 
proved mostly equivocal; MSNA responses do not appear to be different between EF and 
ML menstrual cycle phases during handgrip exercise or post-exercise occlusion (Jarvis et 
al., 2011), mental stress (Carter & Lawrence, 2007), or the cold pressor test (Middlekauff 
et al., 2012;Jarvis et al., 2011). The cold pressor test has also been repeated in users of 
hormonal contraceptives, with similar sympathetic responses observed between LH and 
HH phases as well (Middlekauff et al., 2012). Taken together with MSNA responses to 
simulated orthostasis, these data suggest that if hormone phases affect neural regulation 
during sympatho-excitation, it is in a reflex-dependent manner. Interestingly, there have 
been no studies to date which have systematically compared the sympathetic responses to 
chemoreflex stimulation between hormone phases in users or non-users of hormonal 
contraceptives. The lack of research in this area was another impetus for these studies. 
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Chapter 2  
2 Hormone phases influence neurovascular responses to 
high levels of lower body negative pressure 
2.1 Introduction 
There exists an increased incidence of orthostatic intolerance in young women 
relative to young men (Montgomery et al., 1977;Christou et al., 2005;Hordinsky et al., 
1981). Orthostatic stress tolerance is contingent upon adequate neurovascular responses 
to compensate for the gravity-induced peripheral pooling of blood. As such, several 
studies have made use of the microneurography technique to determine whether a 
reduced muscle sympathetic nerve activity (MSNA) response might contribute to the 
increase in orthostatic intolerance in women. While some studies have reported that 
MSNA responses to simulated orthostasis are blunted in women relative to men 
(Kimmerly et al., 2007;Yang et al., 2012;Shoemaker et al., 2001), some studies have 
determined that MSNA responses are equivocal between the sexes (Fu et al., 2005;Fu et 
al., 2009). It is possible that differences in the concentrations of circulating sex hormones 
in the female subjects may have contributed to this discrepancy in the results, but the 
impact of changes in sex hormones on the regulation of MSNA have only recently begun 
to be elucidated.   
 Recent evidence suggests that concentrations of circulating sex hormones exert an 
influence over the regulation of baseline MSNA (Carter et al., 2013;Day et al., 2011). 
Cyclical changes in sex hormones occur across the regular menstrual cycle, and several 
studies have provided support for a relative sympatho-excitation during the high hormone 
midluteal phase of the menstrual cycle (ML) relative to the low hormone early follicular 
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phase (EF) (Minson et al., 2000a;Park & Middlekauff, 2009;Middlekauff et al., 
2012;Carter et al., 2013). Several studies have also compared sympathetic responses to 
simulated orthostasis. These stimuli cause peripheral pooling of blood which reduces 
venous return and cardiac output and threaten the maintenance of blood pressure. Muscle 
sympathetic neural responses to orthostasis elicit increases in peripheral resistance, 
thereby maintaining blood pressure at baseline levels across mild to moderate levels of 
orthostasis. Sympathetic responses to the simulated orthostasis techniques of head up tilt 
(Fu et al., 2009) and lower body negative pressure (LBNP) (Carter et al., 2009b) are 
elevated in the ML phase relative to the EF phase. Notably, the differences in the MSNA 
responses between EF and ML are greatest during the most severe stages of baroreceptor 
unloading (Fu et al., 2009;Carter et al., 2009b). These studies have also reported a lack of 
change in sympathetic baroreflex sensitivity across the menstrual cycle (Fu et al., 
2009;Carter et al., 2009b). This observation is in line with a greater vascular stress which 
arises from the same orthostatic stimulus, such as a greater fall in stroke volume. 
However, menstrual cycle differences in the orthostasis-induced reduction in stroke 
volume have not yet been observed (Fu et al., 2009).  
 In comparison with studies of the menstrual cycle in eumenorrheic women, less is 
known regarding sympathetic regulation in women taking hormonal contraceptives (HC), 
despite the fact that at least 20% of women of child-bearing age currently use hormonal 
contraceptives (HC) in the United States (Mosher & Jones, 2010). Moreover, HC use has 
been associated with small yet significant increases in blood pressures relative to control 
subjects (Hickson et al., 2011;Atthobari et al., 2007), suggesting that blood pressure 
regulation mechanisms such as the baroreflex may be affected by HC use. Indeed, recent 
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studies have indicated that phases of HC use may not mirror the menstrual cycle in their 
effects on sympathetic regulation. For instance, differences in baseline MSNA have not 
been observed between low- (LH) and high-hormone (HH) phases of HC use (Minson et 
al., 2000b;Carter et al., 2009a;Middlekauff et al., 2012). A study examining sympathetic 
responses to simulated orthostasis observed that moderate levels of LBNP (0 to -40 
mmHg) were associated with similar MSNA responses between LH and HH phases, 
during which blood pressure responses were also similar between phases (Carter et al., 
2009a). However, to the best of our knowledge there have been no studies which have 
directly compared the effects of hormone phases on sympathetic responses to simulated 
orthostasis between users and non-users of HC.   
 Therefore, the purpose of this study was to compare MSNA responses to 
moderate to high levels of LBNP between low- and high-hormone phases of both the 
regular menstrual cycle and HC use. We tested the hypothesis that hormone phase 
(regardless of group) would affect sympathetic and blood pressure responses such that in 
both groups of women the higher hormone phases (HH and ML) would be associated 
with greater sympathetic responses than the lower hormone phases (LH and EF). 
2.2 Methods 
2.2.1 Subjects 
Seventeen undergraduate and graduate students enrolled in the School of 
Kinesiology at The University of Western Ontario in London, Ontario participated in the 
study. These were recruited in two groups: users and non-users of HC. Subject 
characteristics are presented in Table 2.1. The baseline characteristics for the HC group, 
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and their MSNA responses to chemoreflex stress, have been reported previously 
(Usselman et al., 2013).  All subjects were regularly active non-smokers who were free 
of cardiovascular and respiratory disease, and were not taking any medications, with the 
exception of HC. Within users of HC, with the exception of 1 subject who was using a 
patch with norelgestromin and 1 subject using a triphasic pill containing norgestimate, all 
subjects were using monophasic combination pills with either drospirenone (2 subjects), 
desogestrel (1 subject), or levonorgestrel (3 subjects). All HCs contained 20-30 µg of 
ethinyl estradiol. Participants provided signed consent to the study protocols which were 
approved by the Health Sciences Research Ethics Board at The University of Western 
Ontario, Canada, and conformed to the standards set by the Declaration of Helsinki. 
Women in the HC group were tested between days 1 and 4 (day 1 being the first 
day of menstruation) to represent the LH phase which is associated with no contraceptive 
use or placebo use. Women taking HC were also tested between days 20 and 24 to 
represent the HH phase, associated with active hormonal contraceptive treatment. Due to 
the inhibitory effect of exogenous hormones on endogenous hormone production, there 
was no significant change in circulating levels of endogenous 17-β-estradiol or 
progesterone from LH (117 ± 89 pmol/L and 1.0 ± 0.7 nmol/L, respectively) to HH (51 ± 
18 pmol/L and 1.1 ± 0.7 nmol/L; P = 0.1 and 0.6, respectively). Non-users of HC were 
tested between days 1 and 4 of the menstrual cycle during the EF phase, and days 20-24 
during the ML phase. Significant increases in 17-β-estradiol and progesterone from EF 
(151 ± 50 pmol/L and 1.2 ± 0.5 nmol/L, respectively) to ML (638 ± 175 pmol/L and 35.8 
± 9.3 nmol/L) confirmed the target menstrual cycle phases.   
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2.2.2 Experimental Design 
Each subject visited the laboratory on 3 occasions. The first was a familiarization 
visit during which the subjects practiced the LBNP protocol and experienced all non-
invasive aspects of data acquisition. Hormone phase testing occurred following 
familiarization, and the order of hormone phase testing was counterbalanced among the 
subjects. Time of day was kept constant within each subject. Subjects arrived for test 
days a minimum of 3 hours postprandial and having abstained from exercise, caffeine, 
and alcohol for a minimum of 12 hours. Subjects were positioned supine with their legs 
and hips sealed in a LBNP chamber. The LBNP chamber was connected to a vacuum fed 
through a variable transformer (Staco Energy Products Co., Dayton, Ohio, USA) which 
allowed precise control of suction inside the chamber. After subjects had been 
instrumented for data acquisition including microneurography, 5 minutes of stable 
baseline were recorded. Subjects were then exposed to LBNP at -30, -60, and -80 mmHg. 
The order of LBNP testing was quasi-random: -60 mmHg always preceded -80 mmHg to 
ensure that all subjects could tolerate -60 before advancing to -80 mmHg. Therefore, only 
the order of -30 mmHg versus the severe levels of suction was randomized. An additional 
five minutes of baseline were recorded prior each LBNP level to account for any possible 
drift in the sympathetic or hemodynamic signals over the course of the test session. All 
LBNP levels were maintained for 3 minutes, and were tolerated in all subjects except one 
woman who reported mild nausea following LBNP -60 mmHg; LBNP -80 mmHg was 
not conducted in this subject. 
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2.2.3 Measures 
Heart rate (HR) was measured through a 3-lead electrocardiogram. Blood 
pressure waveforms were obtained through finger photoplethysmography (Finometer; 
Finapres Medical Systems, Amsterdam, The Netherlands) and calibrated to a resting 
blood pressure which was the average of three values obtained through manual 
sphygmomanometry. Cardiac output (Q) was calculated online using the Modelflow 
algorithm (Finometer). Muscle sympathetic nerve activity was assessed through 
microneurography at the peroneal nerve (Vallbo et al., 1979). Briefly, a tungsten 
recording electrode with an uninsulated tip was inserted transcutaneously and an 
additional electrode was inserted subcutaneously as reference. The recording electrode 
was maneuvered into the nerve until a recording site was obtained. Adequate recording 
sites were associated with pulse synchronous bursts of activity which increased in 
frequency during end-expiratory apnea and were unaffected by arousal to a loud noise 
(Delius et al., 1972). The MSNA signal was amplified 1000x by a preamplifier and 75x 
by a variable-gain, isolated amplifier, then band-pass filtered from 700 to 2000 Hz. The 
signal was then rectified and integrated (0.1 s time constant; model 662C-3; Iowa 
University Bioengineering, Iowa, USA). The MSNA signal was sampled at 10 000 Hz by 
an online data acquisition and analysis package (Powerlab /16SP with LabChart 7, 
ADInstruments, Colorado Springs, Colorado, USA). Hemodynamic measures were 
sampled at 1000 Hz. 
2.2.4 Data Analysis 
Mean arterial pressure (MAP), systolic (SBP), diastolic (DBP), and pulse 
pressures (PP) were calculated from the calibrated brachial blood pressure waveform. 
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Stroke volume (SV) was calculated as Q divided by HR. Total peripheral resistance 
(TPR) was calculated as MAP divided by Q. Total MSNA was calculated as burst 
frequency (bursts/min) multiplied by mean normalized burst amplitude; burst amplitudes 
were normalized within each LBNP condition by expressing all bursts relative to the 
largest burst in the preceding baseline period, which was assigned a value of 100.  
 All data were analysed statistically using mixed repeated measures analyses of 
variance (ANOVA; Statistical Analysis System V.9.1.3, SAS Institute Inc., Cary, NC, 
USA). At baseline, a 2-way mixed ANOVA assessed the main effects of group (HC vs no 
HC) and hormone phase (EF/LH vs ML/HH) on the sympathetic and hemodynamic 
outcome measures, as well as possible group x phase interactions. Responses to LBNP 
were assessed using a 3-way mixed ANOVA, which assessed the main effects of group, 
phase, and experimental condition (BSL, -30, -60, and -80 mmHg LBNP). These 
analyses on responses to baroreceptor unloading were performed in a slightly smaller 
group than baseline comparisons: 7 women taking HC and 7 women not taking HC. The 
Tukey-Kramer correction was applied in all post hoc comparisons. Alpha was set at 0.05. 
2.3 Results 
Baseline hemodynamics and MSNA characteristics are summarized in Table 2.2. 
No differences were observed in MSNA or hemodynamics between users and non-users 
of HC. A main effect of hormone phase was observed for HR which was significantly 
greater in the high versus low hormone phases. Likewise, MSNA burst frequency and 
total MSNA were elevated in the high hormone phases relative to the low hormone 
phases.  
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 Baroreceptor unloading by LBNP was associated with increases in MSNA burst 
amplitude, burst frequency, and total MSNA (Figure 2.1). A main effect of hormone 
phase indicated that higher hormone phases were associated with higher levels of total 
MSNA and burst frequency than the lower hormone phases while there was no 
significant effect of hormone phase on burst amplitude. These patterns of sympathetic 
activation were not different between users and non-users of HC.  
 The higher hormone phases were associated with higher HR and lower SV 
relative to the lower hormone phases (Figure 2.2). Conversely, the reductions in Q and 
MAP and increases in TPR were similar between low and high hormone phases. 
However, significant group x LBNP interactions were observed for MAP and TPR. These 
indicated that MAP was reduced during LBNP only in women taking HC while TPR was 
increased only in non-users of HC.  
In order to determine whether the exaggerated MSNA responses observed in the 
high hormone phases were accounted for by the greater reductions in SV, we performed 
regression analyses to determine the slope of the relationship between the change in SV 
and the change in MSNA across the 3 levels of LBNP (Figure 2.3). Significant, negative 
relationships were observed between Δ-SV and Δ-total MSNA during both low hormone 
(R = -0.7) and high hormone phases (R = -0.6), the slopes of which were not different 
between hormone phases.  
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Table 2.1: Subject characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are mean ± standard deviation. BMI, body mass index; HC, hormonal 
contraceptives. 
  
 HC Users Non-Users of HC 
n 8 9 
Age (y) 24 ± 3 24 ± 3 
Height (cm) 167 ± 3 166 ± 6 
Weight (kg) 60 ± 4 64 ± 9 
BMI (kg • m2) 22 ± 2 23 ± 3 
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Table 2.2: Baseline hemodynamics and muscle sympathetic nerve activity 
 
Values in central columns are mean ± standard deviation in women taking hormonal 
contraceptives (n=8) during low- (LH) and high-hormone (HH) phases and in women not 
taking exogenous hormones during early follicular (EF) and midluteal (ML) phases of the 
menstrual cycle. Rightmost columns are split-plot ANOVA P values for the main effect 
of hormone phases (EF/LH versus ML/HH). No significant main effects of  group (HC 
users versus non-users of HC) or phase x group interactions were observed. HC, 
hormonal contraceptives; MAP, mean arterial pressure; SBP, systolic blood pressure; 
DBP, diastolic blood pressure; PP, pulse pressure; HR, heart rate; Q, cardiac output; SV, 
stroke volume; TPR, total peripheral resistance; MSNA, muscle sympathetic nerve 
activity.   
 HC Users Non-Users of HC Hormone 
Phase 
P Value  LH HH EF ML 
MAP (mmHg) 92 ± 4 96 ± 9 86 ± 6 84 ± 6 0.5 
SBP (mmHg) 119 ± 10 123 ± 14 114 ± 13 112 ± 10 0.7 
DBP (mmHg) 68 ± 4 70 ± 8 67 ± 9 67 ± 4 0.7 
PP (mmHg) 51 ± 7 53 ± 10 48 ± 18 44 ± 10 0.7 
HR (beats · min-1) 64 ± 8 68 ± 13 61 ± 7 64 ± 7 0.03 
Q (L · min-1) 5.1 ± 0.7 5.6 ± 1.0 4.9 ± 1.0 5.1 ± 1.0 0.2 
SV (mL) 81 ± 13 83 ± 10 80 ± 10 80 ± 14 0.7 
TPR (mmHg  
· L-1 · min-1) 18 ± 2 18 ± 3 18 ± 3 17 ± 5 0.7 
MSNA burst 
frequency 
(bursts · min-1) 
11 ± 7 16 ± 8 10 ± 5 14 ± 6 <0.01 
Total MSNA (a.u.) 493 ± 303 740 ± 398 466 ± 203 740 ± 306 <0.01 
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Figure 2.1: Sympathetic nerve activity during lower body negative pressure across 
hormone phases. 
Total muscle sympathetic nerve activity (MSNA) was elevated in the menstrual cycle 
phases associated with elevated hormones (ML and HH) relative to the low hormone 
phases (EF and LH) across all levels of baroreceptor unloading, regardless of exogenous 
hormone use. HC, hormonal contraceptives; EF, early follicular; LH, low hormone; ML, 
midluteal; HH, high hormone; BSL, baseline. Values are means ± standard deviations. 
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Figure 2.2: Hemodynamic responses to lower body negative pressure across 
hormone phases  
Stroke volume (SV) was lower during the high hormone phases (HH and ML) relative to 
the low hormone phases (LH and EF), while heart rate (HR) was higher during the high 
hormone phases, thus cardiac output (Q) was similar between phases. All of SV, HR, and 
Q were similar between women taking and not taking hormonal contraceptives. LBNP 
was associated with an increase in total peripheral resistance (TPR) only in women not 
taking contraceptives. Mean arterial pressure (MAP) was reduced during LBNP only in 
women taking contraceptives. Values are means ± standard deviations.  
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Figure 2.3: Associations between stroke volume and sympathetic nerve activity 
during lower body negative pressure 
The change in stroke volume (SV) during lower body negative pressure (LBNP) was 
negatively associated with the change in total muscle sympathetic nerve activity (MSNA) 
in both low hormone and high hormone conditions. The slopes of the SV-MSNA 
relationships were similar between hormone phases (-75 ± 55 a.u./mL vs -110 ± 58 
a.u./mL, low hormones vs high hormones; P=0.2). Thin lines are individual subject data 
across LBNP -30, -60, and -80; thick lines represent the mean relationships between Δ-
SV and Δ-MSNA.  
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2.4 Discussion 
This study compared sympathetic responses to moderate to severe levels of LBNP 
during low and high hormone phases of the endogenous menstrual cycle and exogenous 
hormonal contraceptive use. We observed several main findings. First, baseline MSNA 
levels were similar between users and non-users of HC. In both groups of women, MSNA 
burst frequency and total MSNA were reduced during the lower hormone phases (LH and 
EF) compared to the higher hormone phases (HH and ML). Second, the sympathetic 
responses to LBNP were greater in the higher hormone phases than the lower hormone 
phases of both groups. In users and non-users of HC, the exaggerated sympatho-
excitation associated with the higher hormone phase occurred in response to greater falls 
in SV, suggesting a relative increase in the severity of baroreceptor unloading in the 
higher hormone phases compared with the lower hormone phases. Finally, an LBNP-
driven increase in TPR was observed only in women not taking HC. No increase in TPR 
was observed in women taking HC, and as such, HC users experienced a significant fall 
in MAP, which was not observed in non-users of HC. Together, these data indicate that 
higher hormone phases of the menstrual cycle and HC use are associated with greater 
baroreceptor-mediated increases in sympathetic nerve activity than the lower hormone 
phases. However, the resultant end-organ responses associated with sympathetic nerve 
activation may be affected by HC use.  
 An increase in baseline MSNA from the low hormone to the high hormone phase 
has been observed several times in non-users of HC, with heightened MSNA observed in 
the ML phase of the menstrual cycle relative to the EF phase (Minson et al., 2000a;Park 
& Middlekauff, 2009;Middlekauff et al., 2012;Carter et al., 2013). However, a similar 
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pattern has not yet been observed across low and high hormone phases of HC use 
(Minson et al., 2000b;Carter et al., 2009a;Middlekauff et al., 2012). It is possible that 
differences between endogenous hormones and the exogenous hormones in 
contraceptives may contribute to this discrepancy. Significant correlations have been 
observed between the magnitude of the increases in endogenous 17-β-estradiol (E2) and 
progesterone from EF to ML and the increase in MSNA burst frequency across the 
menstrual cycle (Carter et al., 2013). Specifically, the largest ML phase-driven increases 
in MSNA coincided with limited increases in E2 and larger increases in progesterone, in 
support of a sympatho-inhibitory influence of E2 and a sympatho-excitatory influence of 
progesterone (Carter et al., 2013). Along similar lines, some progestins commonly used 
in HC have androgenic properties, and an androgenic hormonal milieu has been 
associated with elevations in baseline MSNA in a clinical population of women 
(Sverrisdottir et al., 2008). Therefore, while the increased progestin concentrations 
associated with the HH phase of HC use could potentially elevate MSNA, all of the 
progestins contained in the contraceptives used in the present study have low androgenic 
activity (Speroff & DeCherney, 1993) and/or antiandrogenic activity (Fuhrmann et al., 
1996). Thus, it remains unclear why an increase in MSNA was observed in the women 
taking HC in the present study, in contrast to the previous studies (Minson et al., 
2000b;Carter et al., 2009a;Middlekauff et al., 2012).  
 Previous studies examining the sympathetic responses to baroreceptor unloading 
across the menstrual cycle in women in non-users of HC have used mild to moderate 
LBNP (-5 to -40 mmHg) (Carter et al., 2009b) and prolonged 60° head-up tilt (Fu et al., 
2009).  Both studies observed greater increases in total MSNA in the ML phase than the 
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EF phase. On the other hand, the same effect has not been observed in women taking HC: 
graded LBNP up to -40 mmHg resulted in similar MSNA responses between LH and HH 
phases of HC use (Carter et al., 2009a). However, in each of these previous studies, 
hemodynamic responses to baroreceptor unloading were similar between hormone phases 
(Carter et al., 2009a;Carter et al., 2009b;Fu et al., 2009), in contrast with the present 
study.   
In the present study, acute, severe LBNP was used to evoke large sympatho-
excitatory responses driven by baroreceptor unloading. Unlike previous studies, the SV 
stimulus and MSNA response were greater in high hormone phases (ML and HH) than 
low hormone phases (EF and LH).  Total MSNA increases were linearly related to the 
decrements in SV in both low and high hormone conditions. Moreover, the slope of this 
relationship was similar between hormone phases, indicating similar baroreceptor-driven 
MSNA sensitivity across hormone phases. In other words, these results indicate that the 
greater sympathetic response in high hormone phases was due to greater baroreceptor 
unloading rather than a centrally driven amplification of the efferent sympathetic 
response. These observations confirm those of Middlekauff and colleagues (Middlekauff 
et al., 2012) who showed that sympathetic baroreflex sensitivity was similar between low 
and high hormone phases of both the menstrual cycle and HC use as assessed by the 
modified Oxford test. On the other hand, Minson and colleagues have also used the 
modified Oxford model of baroreflex assessment in comparisons of hormone phases in 
users and non-users of HC, and observed greater sympathetic baroreflex sensitivity in the 
ML phase of the endogenous menstrual cycle relative to the EF phase (Minson et al., 
2000a) while users of HC experience increased sympathetic baroreflex sensitivity in the 
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LH phase relative to the HH phase (Minson et al., 2000b). Thus, although evidence exists 
to indicate that sympathetic responses to a given stimulus of baroreceptor unloading are 
similar between women taking and not taking HC, further work is required in this area.  
In the present study, the only statistical difference between the users and non-
users of HC was observed in the hemodynamic outcomes during LBNP.  In women not 
taking exogenous hormones, LBNP was associated with a small but significant increase 
in TPR, an effect which was not observed in the users of HC. The reduction in cardiac 
output during LBNP was similar between both groups of women, therefore MAP was 
maintained in non-users of HC but reduced in users of HC. These data are suggestive of a 
reduced neurovascular response to an acute orthostatic challenge in women taking HC. 
Previously, Carter and colleagues repeated a graded LBNP protocol from -5 to -40 
mmHg in women across the endogenous menstrual cycle and in women taking HC in 
both the low and high hormone phases (Carter et al., 2009b;Carter et al., 2009a). In these 
studies, the authors observed no significant changes in MAP with LBNP in either group 
of women. However, their levels of LBNP were less severe than those used in the current 
study. The combined data illustrate the potential deleterious impact of HC on 
neurovascular and blood pressure control, but an effect that is observed only at high 
levels of stress.  
Limitations 
 The type of hormonal contraceptive was not controlled in this study, and although 
all subjects were using combination formulations, the type of progestin varied among the 
subjects. Given the varying effects that different progestins exert over endothelial 
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function (Meendering et al., 2010;Meendering et al., 2009;Torgrimson et al., 2007), it is 
unclear to what extent the hemodynamic measures in this study were affected by the 
range of HC types. Also, this experimental design compared phases in which 
progesterone or progestins were elevated at the same time as E2 or ethinyl estradiol. 
These hormones are thought to exert opposing influences over sympathetic regulation 
(Carter et al., 2013), and in the present design we could not tease apart these separate and 
perhaps competing influences.  
Perspectives 
 In this study we did not observe a difference in sympathetic regulation between 
users and non-users of hormonal contraceptives. In both groups, similar lower body 
negative pressure stimuli were associated with greater reductions in SV in the high 
hormone phases, implying more severe venous pooling occurred for a given level of 
negative pressure relative to the low hormone phases. As a result, the sympathetic 
responses to lower body negative pressure were greater during the high hormone phases 
than the low hormone phases. However, the subsequent increase in total peripheral 
vascular resistance was dependent on whether or not a woman was taking hormonal 
contraceptives. Women taking hormonal contraceptives lacked the reflex increase in 
vascular resistance during baroreceptor unloading, and as a result mean arterial pressure 
was not maintained during LBNP as it was in women not taking exogenous hormones. 
These results suggest that both hormone phase and use of HC influence the regulation of 
blood pressure during acute orthostasis in young healthy women.  
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Chapter 3  
3 Hormone phase dependency of neural responses to 
chemoreflex-driven sympatho-excitation in young women 
using hormonal contraceptives 
(Published in J Appl Physiol 115(10): 1415-1422, 2013. Used with permission – see 
Appendix D) 
3.1 Introduction 
Endogenous female sex hormones affect autonomic regulation of the heart and 
vasculature (Saleh et al., 2005;Herbison et al., 2000). Concentrations of circulating sex 
hormones fluctuate across the regular menstrual cycle, and recent studies (Minson et al., 
2000a;Park & Middlekauff, 2009;Middlekauff et al., 2012;Carter et al., 2009b;Jones et 
al., 1996;Fu et al., 2009;Jarvis et al., 2011;Carter & Lawrence, 2007) have used the 
measurement of muscle sympathetic nerve activity (MSNA) to examine whether the 
menstrual cycle affects neural regulation of the peripheral muscle vasculature (Wallin et 
al., 1974). However, despite the high prevalence of oral contraceptive use (Mosher & 
Jones, 2010), relatively few studies have investigated the possible influence that 
fluctuations in exogenous sex hormone levels, brought on through hormonal 
contraceptive use, exert on MSNA.  
Studies that have examined the effect of the menstrual cycle on sympathetic 
activation in young eumenorrheic women not taking hormonal supplementation most 
often compare the early follicular phase, associated with the nadir of estrogen and 
progesterone levels, to the mid-luteal phase, associated with an elevated plateau of these 
hormones. Some (Minson et al., 2000a;Park & Middlekauff, 2009;Middlekauff et al., 
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2012;Carter et al., 2013), but not all (Carter et al., 2009b;Jones et al., 1996;Fu et al., 
2009;Jarvis et al., 2011;Carter & Lawrence, 2007), studies have observed elevated 
baseline MSNA during the mid-luteal phase of the menstrual cycle relative to the early 
follicular phase. Hormone phase-dependent effects on MSNA have been observed during 
baroreceptor unloading (Carter et al., 2009b;Fu et al., 2009) and following mental stress 
(Carter & Lawrence, 2007), with larger MSNA responses and greater baroreflex 
sensitivity (Minson et al., 2000a) during the mid-luteal phase. Thus, the high-hormone 
mid-luteal phase is associated with heightened MSNA relative to the low-hormone early 
follicular phase under conditions of normally-fluctuating endogenous sex hormones.  
While the bulk of recent research has focused on the impact of endogenous sex 
hormone fluctuations in eumenorrheic women, fewer studies have examined the effects 
of exogenous hormone supplementation on MSNA regulation in young healthy women. 
Hormonal contraceptive use has been associated with elevated systolic blood pressures 
(Le-Ha et al., 2012;Hickson et al., 2011) through elevations in arterial stiffness (Hickson 
et al., 2011), which could be attributable to altered patterns of sympathetic outflow in 
these women compared to those previously observed in eumenorrheic women. Thus, in 
order to examine patterns of sympathetic outflow during contraceptive use, three previous 
studies made observations of MSNA at two phases of hormone levels – the low hormone 
phase (LH; brought on through placebo pills or cessation of active pill ingestion) and the 
high hormone phase (HH; the monthly plateau of EE and progestin ingestion). To date, 
the comparison of LH and HH phases has not revealed differences in absolute levels of 
baseline MSNA (Minson et al., 2000b;Carter et al., 2009a;Middlekauff et al., 2012). That 
is, women taking oral contraceptives appear to lack the reduction in MSNA which occurs 
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during the early follicular phase in eumenorrheic women not taking contraceptives. 
However, one study observed higher baseline mean and diastolic blood pressures during 
LH unaccompanied by a difference in MSNA from HH (Minson et al., 2000b), 
suggesting either a change in the transduction of the neural signal into a vascular 
outcome, or a change in central baroreflex integration from LH to HH. To the latter end, 
sympathetic baroreflex sensitivity elicited through the modified Oxford method may be 
greater during the LH phase relative to HH (Minson et al., 2000b) although others have 
failed to replicate that finding using the same technique (Middlekauff et al., 2012) or 
spontaneous measures of sensitivity (Carter et al., 2009a). Similarly, mild to moderate 
levels of lower body negative pressure (Carter et al., 2009a) have elicited similar MSNA 
responses in each hormone phase. Given the severe vasoactive consequences of the 
modified Oxford technique which involves pharmacologically induced depressor 
(nitroprusside) and pressor (phenylephrine) effects (Rudas et al., 1999), it is possible that 
the influence of hormone phase on MSNA control may be observed only under 
conditions of severe stress. Another stressor known to elicit large changes in sympathetic 
discharge patterns is chemoreflex stress (Steinback et al., 2010;Malpas & Ninomiya, 
1992a), but this has not yet been examined in women taking hormonal contraceptives. 
Thus, both the nature and severity of reflex stress may be important in determining sex-
hormone specific effects on sympathetic reflex activation. Taken together, previous 
research suggests that sympathetic regulation may be affected by fluctuations in 
exogenous hormones, although the low hormone-low MSNA, high hormone-high MSNA 
pattern observed in the conditions of cycling endogenous hormones has yet to be 
observed under conditions of contraceptive use.  
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Therefore, the purpose of this study was to compare muscle sympathetic nerve 
activation patterns during LH versus HH phases of exogenous contraceptive hormone use 
across a range of chemoreflexive stimuli. We hypothesized that baseline MSNA and 
sympathetic reflex responses would be greater in the HH phase relative to the LH phase 
of hormonal contraceptive use. 
3.2 Methods 
3.2.1 Participants 
Ten healthy female participants were enrolled in the study after providing written 
informed consent; repeated nerve sites in each hormone phase were obtained in seven 
participants. The seven research subjects were 24 ± 2 years of age, 167 ± 4 cm in height 
and 60 ± 4 kg in weight (BMI  = 22 ± 2 kg/m2). They were healthy non-smokers who had 
no history of cardiovascular or respiratory disease. All participants were physically 
active, performing a combination of aerobic and resistance exercise an average of 4 times 
each week, 50 minutes per day.  Participants were not taking any medications with the 
exception of hormonal contraceptives. Average age of menarche was 12 ± 1 years. 
Hormonal contraceptive data are presented in Table 3.1. All protocols were approved by 
the Health Sciences Research Ethics Board at The University of Western Ontario, 
Canada, and conformed to the Helsinki Accord.  
3.2.2 Experimental Design 
Prior to data collection, all participants attended a familiarization session in the 
same laboratory used for testing at which time they practiced the test protocol and 
experienced the non-invasive components of data acquisition. On test dates, participants 
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arrived at the laboratory at least 3 hours postprandial and having abstained from alcohol, 
caffeine, and other stimulants for 12 hours. Participants were studied twice: during the 
low hormone phase (LH; day 1-4; day 1 = the first day of menses) and during the high 
hormone phase (HH; day 20-24). Phases were designated based on the daily doses of the 
contraceptives. Test sessions were conducted at the same time of day for each subject, 
and the order of hormone phase data collection was counterbalanced among participants. 
3.2.3 Rebreathing and End-Inspiratory Apnea Protocol 
Participants were supine and breathed through a mouthpiece (series 9060, Hans 
Rudolph, Inc., Kansas City, MO) attached to a three-way valve which allowed the subject 
to breathe either room air, or through a Y-connector (VacuMed, Ventura, CA) leading to 
two 3-litre breathing bags. Participants were instrumented with a pulse oximetry ear clip 
(Dura-Y D-YSE, Covidien-Nellcor, Boulder, CO) connected to a pulse oximeter 
(OxiMax N-560, Covidien-Nellcor) to monitor blood oxygen saturation throughout the 
protocol. Gases were analyzed using an infrared carbon dioxide sensor and optical 
oxygen detector fed from a damped micro vacuum sampling pump (ML206 Gas 
Analyzer, ADInstruments, Colorado Springs, CO). These values were calibrated using 
ambient air pressure values and converted to online measurements of oxygen (PO2) and 
carbon dioxide (PCO2) partial pressures. Prior to beginning baseline, subjects filled the 
breathing bags with expired air in preparation for the rebreathing period which followed 
the five minutes of baseline recording.  After baseline collection, the 3-way valve was 
turned to initiate rebreathing, a procedure to induce progressive hypoxia and hypercapnia 
and thereby maximize the sympatho-excitatory stress evoked during the subsequent 
apnea. Once PO2 reached 70 Torr, subjects were instructed to perform the maximal end-
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inspiratory apnea on their next inspiration. Upon exhalation at voluntary cessation of the 
apnea, subjects breathed twice in and out of the bags to allow measurement of the end-
apnea PO2 and PCO2.  
3.2.4 Measurements 
Heart rate (HR) was measured through a standard three-lead electrocardiogram. A 
blood pressure waveform was obtained through finger photoplethysmography while 
online calculations produced continuous brachial artery pressure waveforms and cardiac 
output (Q) measures (Finometer; Finapres Medical Systems, Amsterdam, The 
Netherlands).  
Multiunit recordings of postganglionic sympathetic nerve activity were obtained 
from the peroneal nerve of the right leg by microneurography. When test dates were 
separated by fewer than 4 weeks, microneurography was performed on the left leg on the 
second visit. A tungsten microelectrode (35 mm long, 200 µm diameter, tapered to a 1-5 
µm tip) was inserted transcutaneously into the nerve posterior to the fibular head. A 
reference electrode was positioned subcutaneously 1-3 cm from the recording site. A 
suitable sympathetic nerve site produced a characteristic pulse-synchronous burst pattern 
which increased firing frequency in response to a voluntary apnea but was not associated 
with skin paresthesias or skin afferent activity and was not affected by arousal to a loud 
noise. Neuronal recordings were amplified 1000 times by a preamplifier and 75 times by 
a variable-gain, isolated amplifier before being band-pass filtered at 700 – 2000 Hz and 
then rectified and integrated to obtain a mean voltage neurogram (0.1 s time constant) 
(model 662C-3; Iowa University Bioengineering). Raw, filtered, and integrated MSNA 
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data were sampled at 10 000 Hz (Powerlab Software, ADInstruments). All data were 
stored for offline analysis. 
3.2.5 Data Analysis 
Rebreathing data were selected based on PO2: all data between 85 and 70 Torr 
PO2 (i.e. prior to the beginning of the apnea) were averaged to generate mean responses 
to rebreathing. Apnea data were divided into two halves corresponding to an initial phase 
of relative neural suppression to be followed by a larger sympathetic response.  
Therefore, apnea data for each subject were averaged in two phases hereafter referred to 
as the initial phase (APN-P1) and the latter phase (APN-P2). All relative changes were 
calculated against the 5-minute baseline period.   
After calibrating the reconstructed brachial blood pressure signal to a manual 
sphygmomanometer blood pressure reading obtained at rest, the brachial arterial blood 
pressure waveform was used to calculate systolic blood pressure (SBP), diastolic blood 
pressure (DBP), pulse pressure (PP), and mean arterial pressure (MAP). Total peripheral 
resistance (TPR) was calculated as MAP/Q.   
Sympathetic activity was quantified as burst frequency (bursts/min) and burst 
incidence (bursts/100 heartbeats). Burst amplitudes were normalized to the largest burst 
recorded during the baseline period, which was given a value of 100. To examine burst 
amplitude at LH and HH during baseline conditions, burst amplitude distribution curves 
were generated and the medians of the distributions were compared (Sverrisdottir et al., 
2000). Total MSNA in each condition was calculated as the mean normalized burst 
amplitude x burst frequency.  
65 
 
3.2.6 Statistical Analysis 
 Baseline data were compared between LH and HH using 1-tailed paired t-tests. A 
two-way repeated measures ANOVA was used to examine the main effects of hormone 
phase (LH vs HH) and experimental condition (baseline, rebreathing, APN-P1, and APN-
P2) on the outcome measures. Point-wise comparisons for chemoreflex conditions were 
conducted using two-tailed paired t-tests. Post hoc comparisons were corrected using the 
Bonferroni correction. Alpha was set at 0.05. 
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3.3 Results 
Chemoreflex characteristics are presented in Table 3.2; respiration rate, PO2, and 
PCO2 were similar between LH and HH during baseline, rebreathing, and following 
cessation of the apnea.  
Baseline levels of MAP, SBP, DBP, PP, and TPR were similar between LH and 
HH phases (Table 3.3).  Small differences in HR and Q between phases did not reach 
statistical significance. Baseline MSNA burst incidence and burst frequency were greater 
in the HH phase relative to the LH phase, a pattern observed in the majority of subjects 
(Figure 3.1).  Median MSNA burst amplitude was not different between LH and HH 
(Figure 3.2). 
A sample tracing of a representative subject completing the chemoreflex protocol 
in the LH phase is presented in Figure 3.3.  
The hemodynamic consequences of rebreathing were similar between hormone 
phases (Figure 3.4). Specifically, rebreathing during LH and HH elicited similar levels of 
MAP (P=0.72), Q (P=0.23), and HR (P=0.26). TPR was unchanged during rebreathing 
and was similar between hormone phases.  
 Compared with baseline, rebreathing was associated with significant elevations in 
MSNA burst frequency and amplitude (P<0.05) in both hormone phases (Figure 3.4). The 
HH phase produced higher absolute levels of MSNA burst frequency and burst incidence. 
However, when MSNA firing patterns were expressed relative to baseline levels, no 
differences between LH and HH were observed in rebreathe MSNA levels (Figure 3.5).  
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 Apnea.  Apneas were maintained for similar durations in each hormone phase (22 
± 11 vs 22 ± 7 s, LH vs HH, P=0.90). Relative to APN-P1, APN-P2 produced larger 
increases in MAP and TPR and was associated with a reduction in Q (P<0.05; Figure 
3.4). Changes in these hemodynamics were not statistically different between LH and HH 
during either APN-P1 or APN-P2.  
 Both apnea segments elicited significant increases in all MSNA variables from 
baseline (P<0.01; Figure 3.4). Burst frequency rose to similar absolute levels in each 
hormone phase during APN-P1 (P=0.15) and APN-P2 (P=0.36). As a result of the 
baseline hormone phase-based differences in MSNA firing frequency, the relative 
increases in burst frequency (P=0.03) and incidence (P=0.02) were greater in the LH 
phase than the HH phase in APN-P1 but not APN-P2 (frequency: P=0.11; incidence: 
P=0.23; Figure 3.5). Conversely, burst amplitude increased similarly between hormone 
phases in APN-P1 (P=0.63) while APN-P2 elicited a greater increase in burst amplitude 
in the LH compared to the HH phase (P=0.04; Figure 3.4). Together, these changes in 
burst characteristics contributed to a similar total MSNA response in APN-P1 between 
LH and HH (P=0.49) but a greater total MSNA response in LH than HH in APN-P2 
(P=0.02).  
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Table 3.1: Hormonal contraceptive data 
Contraceptive Type n Daily  EE dose (µg) 
Daily progestin 
dose(s) (mg) 
Alesse monophasic pill 1 20 0.1 
Aviane monophasic pill 1 20 0.1 
Evra 
monophasic 
transdermal 
patch 
1 35* 0.2* 
Minovral monophasic pill 1 30 0.15 
Tri-Cyclen Lo triphasic pill 1 25 0.18, 0.215, 0.25 
Yasmin monophasic pill 1 30 3 
Yaz monophasic pill 1 20 3 
Mean ± S.D.: 26 ± 6 0.8 ± 1.2 
 
Data obtained from pharmaceutical websites. Triphasic pill data presented as week 1, 
week 2, week 3. *=estimated daily dose. EE, ethinyl estradiol. 
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Table 3.2: Baseline and chemoreflex respiration characteristics 
 Respiration Rate (breaths/min) PO2 (torr) PCO2 (torr) 
 LH HH LH HH LH HH 
Baseline 13 ± 3 13 ± 4 126 ± 5 126 ± 6 18 ± 4 18 ± 4 
Rebreathe 13 ± 4 12 ± 4 79 ± 1 79 ± 1 45 ± 4 44 ± 4 
End-Apnea - - 62 ± 3 62 ± 3 49 ± 4 47 ± 4 
Data presented as mean ± standard deviation. PO2 = partial pressure of oxygen; PCO2 = 
partial pressure of carbon dioxide; LH = low hormone phase; HH = high hormone phase.  
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Table 3.3: Baseline hemodynamic and muscle sympathetic nerve activity 
Data presented as mean ± standard deviation. MAP = mean arterial pressure; HR = heart 
rate; SBP = systolic blood pressure; DBP = diastolic blood pressure; PP = pulse pressure; 
Q = cardiac output; TPR = total peripheral resistance; MSNA = muscle sympathetic 
nerve activity. 
  
Variable Low Hormone Phase 
High 
Hormone 
Phase 
P 
Value 
MAP (mmHg) 99 ± 14 103 ± 14 0.22 
HR (beats · min-1) 64 ± 8 71 ± 11 0.06 
SBP (mmHg) 128 ± 16 129 ± 16 0.43 
DBP (mmHg) 70 ± 5 73 ± 12 0.15 
PP (mmHg) 57 ± 13 55 ± 9 0.36 
Q (L · min-1) 5.1 ± 0.7 5.8 ± 0.9 0.08 
TPR (mmHg · L-1 · min-1) 20 ± 4 18 ± 2 0.14 
MSNA burst incidence (bursts · 100 
heartbeats-1) 
16 ± 8 23 ± 9 0.03 
MSNA burst frequency (bursts · min-1) 11 ± 6 16 ± 8 0.02 
Total MSNA (a.u.) 522 ± 270 744 ± 350 0.04 
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Figure 3.1: Individual patterns of sympathetic burst frequency and incidence. 
The majority of subjects increased muscle sympathetic nerve activity (MSNA) firing 
rates from low (LH) to high hormone phases (HH). Closed circles with error bars 
represent LH mean ± standard deviation; open circles with error bars represent HH mean 
± standard deviation. *P<0.05 vs LH.  
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Figure 3.2: Sympathetic burst amplitude distributions at baseline. 
Medians of the distributions were not different between LH and HH phases (P=0.22). 
Data are presented as mean ± standard deviation.  
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Figure 3.3: Sample tracing from a subject performing the rebreathing and apnea 
protocol. 
Data are from low hormone phase. Lines at top represent data selected for analysis. BSL 
= baseline; APN-P1 = initial half of apnea; APN-P2 = latter half of apnea; PO2 = partial 
pressure of oxygen; PCO2 = partial pressure of carbon dioxide; MSNA = muscle 
sympathetic nerve activity; BP = blood pressure; HR = heart rate. 
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Figure 3.4: Hemodynamics and sympathetic activity responses. 
A main effect of chemoreflex was observed across all measures. Significant hormone 
phase x chemoreflex condition interactions were observed in burst frequency and burst 
amplitude. *P<0.05 vs BSL; †P<0.05 LH vs HH. Data are presented as mean ± standard 
deviation. COND = chemoreflex condition; LH = low hormone phase; HH = high 
hormone phase.   
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Figure 3.5: Relative changes from baseline in sympathetic characteristics. 
Greater increases in muscle sympathetic nerve activity (MSNA) in response to 
chemoreflex stimulation were observed in the low hormone (LH) phase compared to the 
high hormone (HH) phase of hormonal contraceptive use. No significant Phase x 
Condition interactions were observed. Data are presented as mean ± standard deviation. 
COND = chemoreflex condition.   
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3.4 Discussion 
This study was the first to observe differences in baseline levels of MSNA 
between hormone phases in women taking hormonal contraceptives. Specifically, we 
observed elevations in baseline MSNA burst frequency and burst incidence with no 
change in baseline burst amplitude distribution from the low- to the high-hormone phase 
of hormonal contraceptive use. In addition to baseline effects, hormonal contraceptives 
also affected the reflex increase in MSNA, but in a manner that was different than 
baseline effects. Specifically, severe chemoreflex stimulation elicited greater increases 
from baseline in sympathetic firing frequency and burst amplitude in the LH phase 
relative to the HH phase. Importantly, the greater chemoreflex response in the LH phase 
included a shift in burst amplitude distribution suggesting greater neuronal recruitment.  
Therefore, these data suggest that endogenous hormone phase affects the regulation of 
muscle sympathetic nerve activity both at baseline and during chemoreflex stress.  
 In the current study, elevated baseline MSNA in the HH phase relative to the LH 
phase was observed without concurrent change to blood pressure, Q, or TPR. While 
previous studies have not observed baseline differences in MSNA between LH and HH 
(Minson et al., 2000b;Carter et al., 2009a;Middlekauff et al., 2012), Minson and 
colleagues (Minson et al., 2000b) observed reduced baseline MAP and diastolic blood 
pressure, with elevated calf blood flow and a trend toward reduced calf vascular 
resistance (P=0.06) during the HH phase relative to LH. In the presence of similar 
MSNA, this points to a reduction in the transduction of the neural signal into a vascular 
outcome in the HH phase of hormonal contraceptive use, which is consistent with the 
data from the present study.  It is possible that changes to the hormonal milieu induced 
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through contraceptive use may contribute to the change in baseline sympathetic 
regulation, as research conducted in eumenorrheic women without hormonal 
supplementation suggests that the concentrations of circulating hormones affect baseline 
MSNA. A recent study by Carter and colleagues (Carter et al., 2013) retrospectively 
correlated circulating concentrations of estradiol and progesterone to resting MSNA in 30 
young premenopausal women who were not taking any exogenous hormones. In their 
analysis comparing the magnitude of the change in hormone levels from the early 
follicular to the mid-luteal phase to the magnitude of the increase in MSNA across the 
menstrual cycle, the authors observed that smallest changes in the ratio of estradiol to 
progesterone were associated with the greatest increases in baseline MSNA (Carter et al., 
2013), suggesting that increasing levels of progesterone promote sympathoexcitation, 
while elevated levels of estradiol are associated with sympathoinhibition. Furthermore, 
sex hormones are well known to be vasoactive; the influence estrogens exert over the 
vasculature has been the subject of thorough review (Miller & Duckles, 2008). Estradiol 
administration enhances basal nitric oxide release in resistance arteries (Sudhir et al., 
1996), which would counteract MSNA-induced vasoconstriction. Conversely, 
progesterone antagonizes the vasodilatory properties of estradiol observed during FMD 
(Miner et al., 2011). Together, these data support a hormonal basis for the menstrual 
cycle-based changes in MSNA observed in eumenorrheic women since the mid-luteal 
phase, associated with high progesterone and estradiol, is associated with heightened 
MSNA (Minson et al., 2000a;Park & Middlekauff, 2009;Middlekauff et al., 2012;Carter 
et al., 2013). Similar patterns observed in the present study suggest that it is the hormone 
levels which are driving phase-based changes in MSNA in women taking hormonal 
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contraceptives. However, it is important to note that endogenous and exogenous 
hormones differ in their physiological effects. Ethinyl estradiol is not oxidized the same 
way as endogenous estradiol, thus its potency is much greater than the endogenous 
counterpart (Kuhl, 2005). Endogenous progesterone and the synthetic progestins vary in 
their progestogenic, antiestrogenic, and androgenic effects, dependent on the presence of 
molecular subgroups which determine receptor binding (Kuhl, 2005). Even within the 
realm of synthetic hormones, the vascular effects of various progestins are dependent on 
the precise progestin studied (Meendering et al., 2010;Meendering et al., 2009). Thus, 
caution must be taken when applying conclusions based on endogenous hormones to 
exogenous hormonal supplementation. This issue is further confounded due to the 
complexities involved in quantifying the hormonal milieu in women supplementing 
endogenous hormone production with exogenous hormones. Bioavailability of exogenous 
hormones varies among individuals (Goldzieher & Stanczyk, 2008), metabolites of 
hormones may remain in tissue for days following cessation of contraceptive use 
(Wenner & Stachenfeld, 2012), and endogenous production of hormones can increase 
during hormonal contraceptive withdrawal (van Heusden & Fauser, 1999). A complete 
picture of circulating hormone levels in women taking hormonal contraceptives would 
therefore require the measurement of both exogenous and endogenous levels of sex 
hormones. However, conventional ELISA techniques are plagued by cross-reactivity 
between ethinyl estradiol and 17β-estradiol. This issue requires further attention with 
precise quantification of hormone levels, such as those achieved through mass 
spectrometry, in order to determine the extent to which circulating hormones exert an 
influence over baseline MSNA.  
79 
 
 The present study was the first to compare chemoreflex-induced increases in 
MSNA across the phases of hormonal contraceptive use. The application of progressive 
chemoreflex stress (i.e. rebreathing then apnea) revealed hormone phase-specific effects 
based on severity of chemoreflex stimulation. For instance, mild chemoreflex stimulation 
during rebreathing did not change overall patterns of MSNA from those observed at 
baseline. However, despite the lower baseline levels of MSNA, the LH phase was 
associated with greater relative changes in MSNA burst frequency and incidence during 
the initial phase of apnea, as well as greater increases in burst amplitude in the latter 
phase of the apnea, such that total MSNA in the LH phase exceeded that observed in the 
HH phase during the most severe chemoreflex condition examined in this study. These 
observations suggest that elevated baseline activity in HH may encroach upon the ceiling 
of maximal sympathetic outflow. The current observations are supported by previous 
observations insofar that mild to moderate baroreceptor unloading (Carter et al., 2009a) 
did not elicit hormone phase-dependent differences in MSNA regulation while 
application of the modified Oxford method, which induces large, supraphysiological 
fluctuations in MAP, revealed greater sympathetic baroreflex sensitivity in subjects in the 
LH phase (Minson et al., 2000b).  Therefore, it appears to be important to examine a 
range of severities in sympatho-excitatory stimuli when examining the effects of 
hormonal contraceptive use on sympathetic regulation.  
The most commonly reported characteristics of MSNA are burst frequency, a 
general indicator of efferent sympathetic outflow (what the end organ “sees”), and burst 
incidence, which takes into account the central integration of beat-to-beat afferent 
feedback originating from the baroreceptors. Burst amplitude, however, is reported less 
80 
 
often, yet is correlated to the magnitude of vascular responses (Fairfax et al., 2013) and is 
controlled in a manner different from burst frequency (Sverrisdottir et al., 
2000;Kienbaum et al., 2001;Malpas & Ninomiya, 1992b). This supports the presence of 
two discrete mechanisms by which vasoconstrictor signals might be altered: strength and 
occurrence of sympathetic bursts (Kienbaum et al., 2001). The quantification of burst 
amplitude presents a difficulty, as raw amplitude values are indicative of recording 
electrode placement within the nerve (Vallbo et al., 1979) and/or axonal recruitment 
(Ninomiya et al., 1993). However, when  raw burst amplitude voltages are normalized 
and expressed as burst distribution plots, changes in the distribution of burst amplitude 
have been shown to discriminate between conditions where similar levels of burst 
frequency were observed (Sverrisdottir et al., 2000;Shoemaker et al., 2001). In the 
present study, the distribution of burst amplitude was similar between LH and HH during 
conditions in which burst frequency and incidence were different between hormone 
phases. In the latter half of the apnea condition, however, in which firing frequencies had 
approached maximal levels and no longer differed between LH and HH, burst amplitude 
increased in the LH phase, resulting in overall greater total MSNA in the LH phase 
relative to the HH phase during severe chemoreflex stress. These data emphasize the 
importance of burst amplitude as a mechanism by which alterations to peripheral nerve 
activity may be accomplished, particularly when burst frequencies are at or near maximal 
levels.  
Limitations 
 The end-inspiratory apnea protocol was designed to maximize sympathetic 
activation. Although the technique would affect primarily a change in chemoreflex stress, 
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the increases in intrathoracic pressures which accompany such apneas will also affect 
cardiac function and baroreflex contributions to the response. Also, the chemoreflex 
protocol induced concurrent hypercapnia and hypoxia. Therefore, whether hormone 
phase has an effect on the singular stimulus of hypoxia or hypercapnia on MSNA remains 
unknown.   
Importantly, the participants in the current study were taking different hormonal 
contraceptives, with one subject taking a transdermal patch and one subject taking a 
triphasic pill formulation. While all contraceptives contained relatively similar amounts 
of EE, the type and amount of progestin varied, and these factors are known to affect 
vascular function (Meendering et al., 2010;Meendering et al., 2009). Therefore, it is 
unclear how the specific types of hormonal contraceptives contributed to our findings.  
Conclusions 
 The data from the present study support the conclusion that exogenous sex 
hormones exert an effect on baseline sympathetic outflow, in a manner which similar to 
that observed in studies examining regularly cycling women not taking hormonal 
contraceptives (Minson et al., 2000a;Park & Middlekauff, 2009;Middlekauff et al., 
2012;Carter et al., 2013). Specifically, baseline MSNA was higher in the high hormone 
phase. Moreover, chemoreflex-driven sympathetic responses (both burst frequency and 
amplitude) were smaller in the HH versus the LH phase. Thus, the higher baseline MSNA 
levels in HH did not translate into high maximal levels of sympathetic outflow. 
Observations of similar hemodynamic outcomes in the face of altered MSNA imply a 
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contraceptive phase-dependent change in the transduction of neural inputs into vascular 
outcomes.  
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Chapter 4  
4 Sex and menstrual cycle effects on sympathetic 
responses to chemoreflex activation 
4.1 Introduction 
Rates of cardiovascular morbidity and mortality tend to be lower in premenopausal 
women than in age-matched men (Rosenthal & Oparil, 2000;Eaker et al., 1989;Criqui et 
al., 1985). Included in the category of morbidity are the sleep apnea syndromes, which 
are more prevalent in men than in women (Young et al., 1993). Sleep-disordered 
breathing is associated with elevated MSNA (Hedner et al., 1988;Carlson et al., 1993) 
and is an independent risk factor for hypertension (Hla et al., 1994), an association which 
may be strengthened in men relative to women (Nieto et al., 2000). However, the factors 
contributing to the elevated risk in men are not yet well established (Jordan & McEvoy, 
2003).  
Given that individuals with sleep apnea experience repeated bouts of hypoxia and 
hypercapnia over the course of a night, the relative female protection from sleep apnea 
may stem from an improved ability to respond to chemoreflex stress. In a study of the 
sympathetic responses to acute hypoxic stress in humans, muscle sympathetic nerve 
activity increased with a shorter latency in women relative to men, and following 
cessation of hypoxia returned back to baseline levels faster than men (Jones et al., 1999). 
Together with data indicating that females are better able to survive prolonged exposure 
to hypoxia than males (Britton & Kline, 1945), these data support a sex effect on 
sympathetic regulation in response to hypoxic stress. However, the apneic events which 
accompany sleep apnea are associated with a combination of hypoxia and hypercapnia, 
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and it is not yet known whether the sympathetic response to this combined stimulus 
differs between men and women.  
In the consideration of sympathetic regulation mechanisms in women, several 
recent studies suggest that menstrual cycle should be taken into account. For instance, 
several studies have observed that muscle sympathetic nerve activity (MSNA) peaks 
during the midluteal (ML) phase of the menstrual cycle, associated with elevations in 
17β-oestradiol (E2) and progesterone (P4), and declines during the early follicular (EF) 
phase, associated with the nadir of E2 and P4 (Minson et al., 2000;Park & Middlekauff, 
2009;Middlekauff et al., 2012;Carter et al., 2013). This same pattern has been observed 
during baroreceptor unloading, which elicits reflex increases in MSNA that are larger in 
the ML phase than in the EF phase (Fu et al., 2009;Carter et al., 2009). Furthermore, the 
differences in MSNA responses between menstrual cycle phases are exaggerated as the 
magnitude of baroreceptor unloading is increased (Fu et al., 2009;Carter et al., 2009), 
suggesting that the observation of menstrual cycle-based effects on sympathetic 
regulation may depend on the intensity of the stimulus. This hypothesis may be an 
important point to consider when examining responses to the chemoreflex, as the 
stimulation of the chemoreflex is known to elicit large increases in sympathetic nerve 
activity (Morgan et al., 1995;Saito et al., 1988) which are graded to the intensity and 
duration of the stimulus (Smith & Muenter, 2000).  
To the best of our knowledge, no studies have systematically compared MSNA 
responses to chemoreflex stimulation between EF and ML. However, our laboratory 
recently examined chemoreflex regulation in women who were regular users of hormonal 
contraceptives (Usselman et al., 2013). In those women, the low hormone phase of 
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hormonal contraceptive use was associated with a greater sympatho-excitatory response 
to chemoreflex activation than the high hormone phase (Usselman et al., 2013). If these 
results are generalized to pertain to endogenous hormone phases, this may indicate that 
lower levels of circulating hormones are associated with greater chemoreflex-induced 
increases in MSNA than higher hormone levels. 
Therefore, the purpose of the present study was to compare sympathetic responses 
between men and women during acute, severe chemoreflex stress. We tested the 
hypothesis that hypercapnic-hypoxic rebreathing and apnea would be associated with 
greater increases in MSNA in young healthy women relative to men. To determine 
whether the menstrual cycle is associated with changes in chemoreflex-driven sympatho-
excitation, we compared sympathetic responses in women during the early follicular (EF) 
and midluteal (ML) phases of the menstrual cycle. We tested the hypothesis that the EF 
phase would be associated with greater increases in MSNA than the ML phase. 
4.2 Methods 
4.2.1 Subjects 
Subjects were eligible to participate if they were healthy, non-smoking, free of 
cardiovascular and respiratory disease, and not taking any medications. All women 
reported regular menstrual cycles of approximately 28 days' duration. Data were collected 
from eighteen undergraduate and graduate students enrolled at The University of Western 
Ontario in London, Ontario: nine females (24 ± 3 y, 166 ± 6 cm, 64 ± 9 kg; mean ± 
standard deviation) and nine males (26 ± 2 y, 179 ± 4 cm, 82 ± 11 kg). All participants 
provided written, informed consent. The protocols were approved by the Health Sciences 
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Research Ethics Board at The University of Western Ontario, Canada and conformed to 
the standards set by the latest revision of the Declaration of Helsinki. All subjects were 
physically active, engaging in both endurance and resistance exercise on a regular basis 
(women: 4 ± 2 bouts/week, 81 ± 43 min/bout; men: 5 ± 2 bouts/week, 66 ± 25 min/bout). 
4.2.2 Experimental Design 
Women were tested during EF (days 1-4 after the onset of menstruation) and ML 
(days 20-24) phases of the menstrual cycle. The order of menstrual cycle phase testing 
was counter-balanced. Menstrual cycle phases were confirmed through analysis of the 
hormonal milieu, including measures for E2 (Enhanced Estradiol eE2 assay; Siemens 
ADVIA Centaur Immunoassay System; Siemens Healthcare, Erlangen, Germany), P4 
(Progesterone [PRGE] assay; Siemens ADVIA Centaur Immunoassay System), and 
testosterone (T; Elecsys Testosterone II assay; Roche Cobas e411 Analyzer; Roche 
Diagnostics, Basel, Switzerland) (Table 4.1). Time of day was held constant within each 
subject across test days. 
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Table 4.1: Serum sex hormone levels in women and men 
 
 
 
 
 
 
 
 
 
 
Data presented as mean ± standard deviation. Assay reference ranges, E2: men, ≤ 146 
pmol/L; EF phase, 72-529 pmol/L; ML phase, 205-786 pmol/L; P4: EF phase, 0.5-4.5 
nmol/L; ML phase, 14.0-89.0 nmol/L; T: men, 8.6-29.0 nmol/L; women, 0.3-1.7 nmol/L. 
*P<0.05 versus EF, †P<0.05 versus ML. 
  
 Women 
Men 
 EF ML 
E2 (pmol · L-1) 151 ± 50† 638 ± 175 161 ± 64† 
P4 (nmol · L-1) 1.2 ± 0.5† 35.8 ± 9.3 1.5 ± 0.3† 
T (nmol · L-1) 1.0 ± 0.2 1.0 ± 0.4 19.6 ± 6.5*† 
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Before testing, all subjects attended a familiarization session during which they 
became accustomed to the experimental protocols and the non-invasive aspects of data 
acquisition. On test dates, subjects arrived at the laboratory having fasted for 3 hours, and 
having abstained from caffeine, alcohol, and exercise for 12 hours. Subjects were 
positioned supine and were instrumented following an intravenous blood draw from the 
antecubital vein for the assessment of hormone levels. Sympathetic nerve sites were 
located using microneurography.  
4.2.3 End-Inspiratory Apnea Protocol 
Participants breathed through a mouthpiece (series 9060, Hans Rudolph, Inc., 
Kansas City, MO) attached to a three-way valve which opened to either room air or a Y-
connector (VacuMed, Ventura, CA) leading to two 3-litre rebreathing bags. A nose clip 
prevented nasal breathing (series 9015, Hans Rudolph) and a pulse oximetry ear clip 
(Dura-Y D-YSE, Covidien-Nellcor, Boulder, CO) connected to a pulse oximeter 
(OxiMax N-560, Covidien-Nellcor) was used to monitor blood oxygen saturation. Gases 
were analyzed online using an infrared carbon dioxide sensor and an optical oxygen 
detector fed from a damped micro vacuum sampling pump (ML206 Gas Analyzer, 
ADInstruments, Colorado Springs, CO). In order to maximize the sympatho-excitatory 
stress, a period of rebreathing was conducted immediately preceding the end-inspiratory 
apnea. The order of testing was conducted as follows: (1) subjects filled the rebreathing 
bags with expired air; (2) five minutes of baseline during room air breathing; (3) 
rebreathing to induce progressive hypoxia-hypercapnia; (4) at 70 Torr PO2, maximal end-
inspiratory apnea; (5) upon termination of apnea, subjects breathed twice in and out of 
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the bags for quantification of end-apnea hypoxia-hypercapnia; (6) three minutes of 
recovery data.  
4.2.4 Measurements 
Sympathetic nerve activity was assessed using the microneurographic technique 
(Vallbo et al., 1979). A tungsten recording electrode (diameter: 200 µm, length: 35 mm) 
with an uninsulated 1-5 µm tip was inserted transcutaneously into the peroneal nerve and 
a reference electrode was inserted subcutaneously 1-3 cm from the recording site. 
Adequate MSNA recording sites produced pulse-synchronous bursts of activity which 
increased in frequency during apnea maneuvers and were unaffected by arousal to a loud 
noise (Delius et al., 1972). The MSNA signal was amplified 1000 times by a preamplifier 
and 75 times by a variable-gain, isolated amplifier and then band-pass filtered (700-2000 
Hz). The signal was then rectified and integrated (time constant 0.1 s) (model 662C-3; 
Iowa University Bioengineering, Iowa, USA).  
 Baseline blood pressures were assessed using manual sphygmomanometry; the 
average of three blood pressure values was used to calibrate beat-to-beat blood pressures 
obtained through photoplethysmographic methods (Finometer; Finapres Medical 
Systems, Amsterdam, The Netherlands). Cardiac output (Q) was calculated using the 
Modelflow algorithm in the Finometer. Heart rate (HR) was measured using a standard 3-
lead electrocardiogram. All signals were sampled at 1000 Hz with an online data 
acquisition and analysis package (PowerLab /16SP with LabChart 7, ADInstruments, 
Colorado Springs, Colorado, USA) except MSNA, which was sampled at 10 000 Hz.     
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4.2.5 Data Analysis 
Data from the final section of rebreathing (PO2 between 80 and 70 Torr) were 
averaged to reflect hypercapnia-hypoxia while breathing. Apnea data were divided into 
two halves, corresponding to an initial phase of relative neural suppression (APN-P1) 
followed by the largest sympathetic response occurring during the latter half of the apnea 
(APN-P2). Recovery data were averaged over the final two minutes of recovery, after 
values had returned to baseline levels.  
The brachial blood pressure waveform was analyzed to determine mean (MAP), 
systolic (SBP), and diastolic (DBP) blood pressures. Body surface area was estimated 
using the Mosteller formula (Mosteller, 1987;Lam & Leung, 1988) and was used to 
normalize Q and Q-derived measures to body size in men and women. Q and stroke 
volume were divided by body surface area to determine cardiac index (Qi) and stroke 
volume index (SVi), respectively. Total peripheral resistance (TPR) was calculated as 
MAP/Q. 
 Sympathetic firing frequency was quantified as burst frequency (bursts/min). The 
amplitude component was considered because of its importance in distinguishing 
between conditions which have similar burst frequencies (Sverrisdottir et al., 2000) and 
because burst amplitude is regulated in a manner distinct from burst frequency 
(Kienbaum et al., 2001;Malpas & Ninomiya, 1992) which may reflect axonal recruitment 
(Steinback et al., 2010b;Salmanpour et al., 2011). The amplitude component was 
considered in three ways. Baseline amplitudes were compared between groups and 
conditions through the comparison of frequency probability distribution curves. In this 
baseline analysis, all bursts were scaled to the largest burst in each recording which was 
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assigned a value of 100. The median value of each curve was then used to compare 
normalized burst amplitudes between groups (Sverrisdottir et al., 2000;Kimmerly et al., 
2004). Next, to evaluate changes in burst amplitude during chemoreflex stimulation, all 
burst amplitude voltages during apnea were normalized to the largest amplitude achieved 
during the previous baseline period. The mean normalized burst amplitude during each 
condition was then used to compare between groups. Finally, raw voltages were also 
compared between baseline and recovery periods to validate burst amplitude measures by 
ensuring that sympathetic nerve sites had not shifted during the chemoreflex protocol.  
A representation of the total MSNA signal was calculated by multiplying mean 
normalized burst amplitude by burst frequency. In women, baseline total MSNA was 
regressed against concentrations of circulating sex hormones in the EF phase and in the 
ML phase to determine whether baseline MSNA was graded to the level of circulating 
E2, P4, or T in either phase. Also, to determine whether the magnitude of the increase in 
baseline MSNA from the EF to the ML phase was associated with the magnitude of the 
change in circulating sex hormone concentrations, EF total MSNA levels and sex 
hormone concentrations were subtracted from ML values in each subject. The resulting 
delta values were then regressed against each other.  
4.2.6 Statistical Analyses 
Comparisons of hormones and baseline measures were conducted using paired 
(EF vs ML) or unpaired (men vs EF and ML) T-tests; the alpha value for these and all 
post hoc comparisons were corrected for multiple comparisons using the Bonferroni 
method. Hemodynamic and sympathetic responses to chemoreflex stimulation were 
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analyzed using three separate mixed ANOVAs, comparing (1) EF to ML, (2) men to EF, 
and (3) men to ML. 
4.3 Results 
Baseline subject characteristics are presented in Table 4.2. Sympathetic burst 
frequency and total activity were greater in the ML phase of the menstrual cycle than the 
EF phase. As a result, total MSNA and burst frequency were greater in men than women 
in the EF phase but similar between men and women in the ML phase. Baseline MSNA 
burst amplitude distribution median values were similar between EF (46 ± 13), ML (51 ± 
9), or men (44 ± 7 a.u.). In women, no significant correlations between baseline total 
MSNA and concentrations of circulating E2, P4, or T were observed in either the EF 
phase or the ML phase when the menstrual cycle phases were examined independently 
(Figure 4.1). A significant, positive relationship was observed between the magnitude of 
the ML-phase induced increase in total MSNA and the menstrual cycle-induced increase 
in P4, although this relationship was not observed between total MSNA and E2 or T.  
Apnea characteristics are presented in Table 4.3. Apneas were maintained for 
similar durations and post-apnea PO2 reached similar levels in all groups. Post-apnea 
PCO2 was similar between EF and ML phases, but higher in men relative to the ML 
phase (P=0.01). 
Chemoreflex stimulation was associated with progressive increases in total 
MSNA during rebreathing, APN-P1, and APN-P2 conditions due to elevations in MSNA 
burst frequency and amplitude (Figure 4.2). The increases in total MSNA, burst 
frequency, and burst amplitude were greater in the EF than the ML phase. A statistical 
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interaction between menstrual cycle phase and chemoreflex condition indicated that the 
difference in total MSNA and burst amplitude between EF and ML phases was most 
pronounced during APN-P2. The increases in total MSNA and in burst frequency were 
greater in women in the EF phase than in men, while burst amplitude was not 
significantly different between women and men. All changes in MSNA were similar 
between men and women in the ML phase.  
Individual patterns of changes in MSNA from EF to ML menstrual cycle phases 
are presented in Figure 4.3; from EF to ML menstrual cycle phases, the majority of 
women experienced an increase in baseline total MSNA, and a reduction in peak total 
MSNA as evoked by chemoreflex activation.  
 Hemodynamic responses to chemoreflex stimulation were similar between men 
and women and across menstrual cycle phases with the exception of HR, which was 
greater in women than men (Figure 4.4).  
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Table 4.2: Baseline hemodynamics and sympathetic nerve activity in women and 
men 
Data are mean ± standard deviation. EF, early follicular phase; ML, midluteal phase; 
MAP, mean arterial pressure; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; HR, heart rate; SVi, stroke volume index; Qi, cardiac index; TPR, total 
peripheral resistance; MSNA, muscle sympathetic nerve activity. * P<0.05 vs EF; † 
P<0.05 vs ML 
  
  
 Women  
Men   EF ML 
MAP (mmHg) 86 ± 6 84 ± 6 92 ± 8† 
SBP (mmHg) 114 ± 13 112 ± 11 127 ± 9*† 
DBP (mmHg) 67 ± 9 67 ± 4 73 ± 7 
HR (beats · min-1) 61 ± 7 64 ± 7 54 ± 7*† 
SVi (mL · m2) 47 ± 8 46 ± 7 51 ± 7 
Qi (L · min-1 · m2)  2.9 ± 0.8 3.0 ± 0.6 2.7 ± 0.5 
TPR (mmHg · L-1 · min-1)  18 ± 3 17 ± 5 17 ± 3 
MSNA burst frequency 
   (bursts · min-1) 10 ± 5 14 ± 7* 18 ± 5* 
Total MSNA (a.u.) 466 ± 203 714 ± 317* 854 ± 239* 
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Table 4.3: Apnea characteristics in men and women 
 
 
 
 
 
 
 
 
 
 
 
Data presented as mean ± standard deviation. PO2 = partial pressure of oxygen; PCO2 = 
partial pressure of carbon dioxide; EF = early follicular; ML = midluteal. 
  
 Women 
Men 
 EF ML 
Apnea Duration  
(s) 21 ± 7 22 ± 10 26 ± 8 
End-Apnea PO2 
(Torr) 61 ± 4 61 ± 6 59 ± 4 
End-Apnea PCO2 
(Torr) 54 ± 4 51 ± 3 56 ± 4 
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Figure 4.1: Associations between sympathetic nerve activity and circulating sex 
hormone concentrations at baseline. 
No significant associations between sex hormone concentrations and total muscle 
sympathetic nerve activity (MSNA) were observed in either menstrual cycle phase alone 
(panel A). However, the magnitude of the change in total MSNA from EF to ML was 
positively related to the change in circulating progesterone across the menstrual cycle 
(panel B). EF, early follicular; ML, midluteal. 
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Figure 4.2: Sympathetic responses to chemoreflex stimulation. 
Chemoreflex stimulation was associated with progressive increases in Δ-total MSNA, Δ-
burst amplitude, and Δ-burst frequency in men and women in early follicular (EF) and 
midluteal (ML) menstrual cycle phases (all P<0.001). Δ-Total MSNA and Δ-burst 
frequency were greater in the EF phase relative to both the ML phase and to men. Δ-
Burst amplitude was greater in the EF phase than ML, but not significantly different from 
men. Men had similar MSNA responses as women in the ML phase in all comparisons. 
Significant phase x chemoreflex interactions were observed in Δ-total MSNA (P=0.02) 
and Δ-burst amplitude (P=0.02).Data are mean ± standard deviation. * denotes P<0.05, 
EF vs ML; MSNA, muscle sympathetic nerve activity; BSL, baseline; REBR, 
rebreathing; APN-P1, initial half of apnea; APN-P2, latter half of apnea; REC, recovery.   
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Figure 4.3: Individual patterns of total muscle sympathetic nerve activity across the 
menstrual cycle. 
Panel A contains individual data from all women at baseline; circles and error bars are 
means and standard deviations of EF and ML phases; * denotes P< 0.05 versus EF. Panel 
B shows tracings of 15s of baseline recordings from a representative subject during EF 
and ML phases. Panel C contains individual data from all women during the latter half of 
the apnea (APN-P2). Panel D shows tracings of the end-inspiratory apnea performed 
during EF and ML phases. 
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Figure 4.4: Hemodynamic responses to chemoreflex stimulation. 
Chemoreceptor stimulation was associated with significant changes in mean arterial 
pressure (MAP), heart rate (HR), cardiac index (Qi), and total peripheral resistance (TPR) 
(all P<0.01). Heart rate was higher in women than men. Data are mean ± standard 
deviation. BSL, baseline; REBR, rebreathing; APN-P1, initial apnea half; APN-P2, latter 
apnea half; REC, recovery.  2 
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4.4 Discussion 
In this study, we examined menstrual cycle- and sex-specific regulation of sympathetic 
nerve activity during severe chemoreflex stimulation. We observed that severe 
chemoreflex stimulation elicits reflex increases in total MSNA which are larger in 
women in the EF phase of the menstrual cycle in comparison with men and also with 
women in the ML phase. This occurred as a result of elevations in the burst frequency 
component of MSNA which exceeded those observed in men and in women in the ML 
phase. On the other hand, the chemoreflex response in the burst amplitude component of 
MSNA was affected by menstrual cycle phase, but was not different between men and 
women. We also observed that, across all conditions, patterns of MSNA were similar 
between men and women in the ML phase. Overall, these data indicate that baseline 
MSNA and the sympatho-excitatory responses to severe chemoreflex stress differ 
between men and women, but only when women are measured during the EF phase of the 
menstrual cycle.  
 Many previous studies have compared baseline MSNA between young healthy 
women and men. The first direct comparison of MSNA between men and women, made 
by Ng and colleagues, demonstrated greater resting MSNA burst frequency in men 
relative to women (Ng et al., 1993). Since then, this finding has been reproduced (Jones 
et al., 1996b;Ng et al., 1993;Shoemaker et al., 2001;Matsukawa et al., 1998;Yang et al., 
2012;Jones et al., 1996a;Hart et al., 2009), albeit not consistently (Kimmerly et al., 
2007;Fu et al., 2009;Fu et al., 2005;Jones et al., 1999;Narkiewicz et al., 2005). Of these 
studies, only a few have accounted for menstrual cycle phase in the female subjects 
(Kimmerly et al., 2007;Yang et al., 2012;Hart et al., 2009;Fu et al., 2009). It is likely that 
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this has contributed to the lack of consistency in the observation of sex differences in 
these studies, as elevations in midluteal baseline MSNA have been observed relative to 
the early follicular phase (Minson et al., 2000;Park & Middlekauff, 2009;Middlekauff et 
al., 2012;Carter et al., 2013). Although this observation has not been universal (Carter et 
al., 2009;Jones et al., 1996b;Fu et al., 2009;Jarvis et al., 2011;Carter & Lawrence, 2007), 
recent evidence suggests that changes concentrations of circulating sex hormones, which 
are altered across the menstrual cycle, are associated with changes in baseline MSNA 
(Carter et al., 2013;Day et al., 2011). These studies indicate that acute increases in 
circulating P4 mediate a sympatho-excitatory effect, while increases in E2 promote 
sympatho-inhibition (Carter et al., 2013;Day et al., 2011).However, one study quantified 
the extent to which a ratio of E2-to-P4 was associated with baseline MSNA, and 
determined that only approximately 27% of the variance in MSNA was explained by 
alterations in these sex hormones (Carter et al., 2013). The authors suggested that 
increases in testosterone might occur across the menstrual cycle and contribute to the ML 
phase sympatho-excitation. In the present study we observed no change in testosterone 
across the menstrual cycle, and no associations between testosterone concentrations and 
baseline MSNA. On the other hand, the present data support a positive association 
between the increase in P4 from EF to ML menstrual cycle phases and the magnitude of 
the elevation in resting MSNA.  
 In the present study we also compared sex and menstrual cycle effects on MSNA 
regulation during a strong chemoreflex stimulus. In coupling the sympatho-excitatory 
effect of combined hypoxia-hypercapnia (Morgan et al., 1995) with the elimination of the 
sympatho-inhibitory effect of the thoracic afferent nerves through the use of apnea 
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(Somers et al., 1989;Steinback et al., 2010a), the stimulus was designed to elicit a 
maximal or near-maximal elevation in MSNA.  During chemoreflex activation, increases 
in total MSNA and MSNA burst frequency were greatest in women in the EF phase of 
the menstrual cycle and exceeded the MSNA responses observed in men and in the ML 
phase of the menstrual cycle. These data are in partial support of the previous work which 
reported hypoxia-driven increases in total MSNA which were evoked with a shorter 
latency in women than in men (Jones et al., 1999). However, this previous study did not 
systematically study the effect of menstrual cycle on sympathetic responses to 
chemoreflex stimulation (Jones et al., 1999). Our data, which indicate that chemoreflex-
driven increases in MSNA were similar between men and women in the ML phase, 
suggest that chemoreflex responses are not regulated equally across the menstrual cycle. 
To the best of our knowledge, this is the first study to systematically study sympathetic 
responses to chemoreflex stimulation across the menstrual cycle. However, our 
laboratory recently conducted a similar study in regular users of hormonal contraceptives 
(Usselman et al., 2013). In that previous study, during chemoreflex activation the low-
hormone phase of hormonal contraceptive use was associated with a greater total MSNA 
response than the high-hormone phase (Usselman et al., 2013). Together, these data 
indicate that the patterns of sympathetic responses to severe chemoreflex stress appear to 
be similar between users and non-users of hormonal contraceptives.  
 An interesting observation in this study was the difference between menstrual 
cycle phases in the regulation of the burst amplitude component of MSNA. During the 
EF phase, burst amplitude increased during the most severe phase of chemoreflex 
stimulation, an increase which was not observed during the ML phase. A similar finding 
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was observed in our previous work with regular users of hormonal contraceptives: an 
increase in burst amplitude was observed in the low hormone phase of contraceptive use 
which exceeded that observed in the high hormone phase (Usselman et al., 2013). Also, 
in both the users of hormonal contraceptives and the women examined in the present 
study, the increases in burst amplitude contributed to an overall augmentation of the total 
MSNA response in the low hormone phases relative to the high hormone phases. While 
an elevated burst frequency response was also observed in the EF phase relative to the 
ML, these data might suggest that severe chemoreflex activation preferentially excites the 
burst amplitude, or strength, component of the MSNA signal, an effect which is amplified 
when circulating sex hormone levels are lower. Whether this is due to the removal of an 
inhibitory influence of sex hormones over the amplitude component requires further 
study.  
Limitations 
 Menstrual cycle phases were selected based on the desire to test the nadir of 
hormone secretions (i.e. EF) against a prolonged increase in E2 and P4 production (ML). 
However, we did not study the late follicular phase. In light of our findings, the study of 
this phase would present an interesting opportunity to observe elevated E2 without a 
concurrent change in P4, and perhaps further elucidate the relationship between E2 and 
MSNA.  
 The chemoreflex stress used in this study was designed to elicit large sympatho-
excitatory responses from the subjects. However, the protocol was not designed to 
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differentiate between the specific hemodynamic and sympathetic effects of hypoxia and 
hypercapnia (Steinback et al., 2009).  
 In summary, baseline MSNA burst frequency and total MSNA were affected by 
both sex and the menstrual cycle, and the observation of baseline sex differences were 
menstrual cycle-dependent. Similarly, chemoreflex stimulation produced menstrual 
cycle-dependent sex effects, but to the opposite effect: increases in MSNA burst 
frequency and total MSNA were greater in women than in men, and greater in the EF 
phase than the ML phase of the menstrual cycle.  The menstrual cycle also affected 
MSNA burst amplitude, with larger increases in amplitude in the EF phase relative to the 
ML phase. The results suggest that, when possible, future studies examining sex 
differences in sympathetic activation should include consideration for menstrual cycle 
phase. Future studies may also benefit from examining MSNA in women in more than 
one menstrual cycle phase to generate a more complete picture of factors affecting 
sympathetic regulation in women.   
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Chapter 5  
5 General Discussion 
5.1 Perspectives 
A relatively high level of sympathetic nerve activity is observed in young men in 
comparison with young women (Ng et al., 1993;Matsukawa et al., 1998;Narkiewicz et 
al., 2005). This is thought to be linked to men's higher risk of cardiovascular disease, 
from which women appear to be relatively protected until menopause (Rosenthal & 
Oparil, 2000;Young et al., 1993;Eaker et al., 1989). It is not known, however, why 
women lose this cardioprotection following menopause (Rosano et al., 2007). Similar to 
post-menopausal women, an elevated risk of cardiovascular disease is also present in 
women with polycystic ovary syndrome (Meyer et al., 2012;Ehrmann et al., 
2006;Schlaich et al., 2011). Like post-menopausal women, polycystic ovary syndrome is 
also associated with a change in the sex hormone milieu and an increase in baseline 
sympathetic nerve activity (Abbott et al., 2002;Sverrisdottir et al., 2008). In both cases, 
the roles that sex hormones might play in the alterations to sympathetic and/or 
cardiovascular control are not well described. Also, although synthetic hormone 
supplementation is prescribed as a matter of course in both conditions, the effects of 
synthetic hormones on sympathetic regulation are not well known. Even in young, 
healthy women, knowledge regarding interactions between changes in sex hormones and 
sympathetic regulation has only begun to emerge in the past 15 years. Therefore, in these 
studies we sought to generate a more in-depth understanding of how sympathetic 
regulation patterns relate to changes in hormone levels. We examined acute changes in 
sex hormone levels in young, healthy women free of cardiovascular disease and 
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hormonal abnormalities with the hope that a greater understanding of normal interactions 
between sex hormones and MSNA might help to shed light on the mechanisms which are 
disturbed in clinical states.  
5.2 Major Findings  
 In this series of studies we observed several novel findings regarding interactions 
between sex hormones and MSNA which occur across the menstrual cycle and across 
phases of hormonal contraceptive use. A major finding of these studies was that 
associations between sympathetic nerve activity and hormone phase were not dependent 
on the source of the alteration to the hormonal milieu (i.e. across the menstrual cycle or 
as a result of the use of hormonal contraceptives). In contrast with previous studies 
(Middlekauff et al., 2012;Minson et al., 2000b;Minson et al., 2000a;Carter et al., 
2009a;Carter et al., 2009b), we observed similar muscle sympathetic nerve activation 
patterns between the early follicular phase of the menstrual cycle and the low hormone 
phase of contraceptive use, as well as between the midluteal phase of the menstrual cycle 
and the high hormone phase of contraceptive use. Furthermore, these similarities were 
observed under all conditions, including at baseline and during baroreceptor unloading 
and chemoreflex stimulation. These results imply that the changes in endogenous 
hormones which occur across the menstrual cycle exert a similar influence over the 
regulation of MSNA as the changes in the exogenous hormones contained within the 
hormonal contraceptives used by our subjects. However, it is important to note that while 
all contraceptives used in this study were combination formulations with low doses of 
estradiol and low-androgenic activity progestins, we did not control for the specific type 
of hormonal contraceptive in these studies. Therefore, further research is required to 
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determine why certain hormonal contraceptives may mimic the sympathetic effects of 
endogenous hormones while others may not.  
Another major finding of these studies was that high hormone phases were 
associated with relative elevations in baseline sympathetic nerve activity in comparison 
with the low hormone phases, a trend which was reversed during large, chemoreflex-
induced sympatho-excitatory stress. The hypoxic-hypercapnic end-inspiratory apnea 
produced larger reflex increases in MSNA in the lower hormone phases than those 
observed during the higher hormone phases (see Table 5.1 for a summary of findings). 
Although this observation was initially unanticipated (see Chapter 3), known sex 
differences in sympathetic regulation may provide support for these results. For instance, 
large-scale studies have reported that baseline MSNA is higher in young men than young 
women (Ng et al., 1993;Matsukawa et al., 1998;Narkiewicz et al., 2005). On other hand, 
it has been reported that chemoreflex-driven increases in MSNA are greater in women 
than in men (Jones et al., 1999). These results could be interpreted to indicate that the 
factors which drive relative increases in MSNA at baseline are not effective during 
chemoreflex-driven sympatho-excitation, during which other mechanisms contribute to 
increases in MSNA.  
A main finding of Study 1 (Chapter 2) stemmed from the observation of greater 
reductions in stroke volume for a given lower body negative pressure stimulus during the 
high hormone phases when compared to the low hormone phases. This had not been 
observed by previous studies of simulated orthostasis (Fu et al., 2009;Carter et al., 
2009b;Carter et al., 2009a), although it had been hypothesized to occur (Fu et al., 2009). 
The greater drop in stroke volume implied that a greater unloading of the baroreceptors 
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occurred in the high hormone phases for an equivalent orthostatic stress. Following the 
subsequent normalization of the sympathetic responses relative to baroreceptor stimuli, 
we observed no difference between hormone phases in the sympathetic responses to 
baroreceptor unloading. These data imply that the integration of afferent baroreceptor 
information is unaffected by hormone phase, as had been reported previously (Fu et al., 
2009;Carter et al., 2009b;Middlekauff et al., 2012). 
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Table 5.1: Summary of muscle sympathetic nerve activity results 
  
 
 
 
 
 
 
 
Low (LO) hormone phases are EF phase of menstrual cycle and LH phase of hormonal 
contraceptive use; high (HI) hormone phases are ML phase of menstrual cycle and HH 
phase of hormonal contraceptive use.  
† Stroke volume was lower in ML and HH than in EF and LH, indicating greater 
baroreceptor unloading in these phases. 
†† When normalized to the fall in stroke volume, these responses were no longer 
different between high and low hormone phases.  
‡ Both indicators of chemoreflex stress (partial pressures of oxygen and carbon dioxide) 
and the duration of the apnea were similar between low and high hormone phases, 
indicating a similar sympatho-excitatory stimulus.  
  
 Strength of Stimulus 
Total MSNA 
Response 
MSNA Burst 
Frequency 
Response 
MSNA Burst 
Amplitude 
Response 
Baseline - HI > LO HI > LO LO = HI 
Baroreceptor 
Unloading (LBNP) HI > LO 
†    HI > LO ††    HI > LO †† LO = HI 
Chemoreflex 
Stimulation (Hypoxic-
Hypercapnic Apnea) 
LO = HI ‡ LO > HI LO > HI LO > HI 
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 In this series of studies, separate consideration was given to the regulation of the 
individual components of total MSNA: burst frequency and burst amplitude. This was 
done within the context of the hypothesis that baroreceptor feedback gates efferent 
sympathetic activity, thereby affecting MSNA burst frequency, while other peripheral 
inputs are integrated to regulate MSNA burst amplitude (Malpas, 1995;Kienbaum et al., 
2001). Baseline MSNA recordings indicated a relative increase of MSNA burst frequency 
in the high hormone phases with no change in the regulation of burst amplitude. 
However, chemoreflex activation was associated with a reversal of this trend as greater 
levels of burst frequency were observed in the low hormone phases. Severe chemoreflex 
stimulation was also associated with a large increase in MSNA burst amplitude in the low 
hormone phases which was not observed in the high hormone phases. The baseline data 
suggest that a relatively elevated sex hormone milieu appears to promote the 
augmentation of the burst frequency component of MSNA, which is thought to be 
regulated centrally through a baroreceptor-related mechanism (Kienbaum et al., 2001). 
However, the chemoreflex data suggest that an elevated sex hormone milieu may exert a 
sympatho-inhibitory effect over the burst amplitude component of MSNA. Therefore, 
large reflexive increases in burst amplitude are achieved only in low hormone phases. 
An interesting caveat to the data presented here is that the changes in sympathetic 
responses observed across hormone phases were not coupled with similar changes in 
peripheral resistance. A lack of congruity between MSNA and peripheral resistance has 
been reported previously in young women (Hart et al., 2009). Several explanations have 
been put forth to account for this, including the buffering of the sympathetic signal by 
activation of vasodilatory beta-adrenoreceptors (Hart et al., 2011). Alternatively, the 
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vascular production of nitric oxide is increased by elevations in circulating estradiol 
(Sudhir et al., 1996). An increase in circulating nitric oxide during the midluteal phase of 
the menstrual cycle would exert a dilatory influence over the vasculature, counteracting 
the vasoconstrictor influence of MSNA. Although we did not measure these vascular 
factors in the present study, future research targeting these mechanisms and addressing 
whether they are affected by changes in circulating sex hormones would provide further 
insight into the present findings.   
 In the context of sex hormone effects on sympathetic regulation, future research 
might also address the separate consideration of sex hormones in their possible effects on 
sympathetic nerve activity. The late follicular phase of the menstrual presents an 
opportunity to study sympathetic regulation during an increase in estradiol which is 
unaccompanied by a change in progesterone (Ettinger et al., 1998;Miner et al., 2011). 
Alternatively, short-term changes in circulating hormone concentrations can be elicited 
experimentally through the use of gonadotropin releasing hormone antagonist therapy, 
which dramatically reduces ovarian production of estradiol and progesterone. Estradiol 
and progesterone can then be added back to the subjects independently to examine their 
unique effects. This technique has been coupled with microneurography once to date 
(Day et al., 2011), and while the study was conducted in a small group of women, the 
data indicate a significant sympatho-inhibitory effect of estrogen, and a trend towards a 
sympatho-excitatory effect of progesterone. Further work in this area would shed more 
light on the roles of sex hormones in the regulation of MSNA, and could have 
implications for the development of hormonal treatments of sympathetic irregularities 
within the clinical realm.  
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5.3 Conclusions 
In this series of studies, we have demonstrated for the first time that sympathetic 
responses to chemoreflex stimulation are affected by hormone phases associated with the 
menstrual cycle and hormonal contraceptive use. We have also provided the first 
evidence that the baseline and reflex sympathetic influences of the endogenous hormones 
of the menstrual cycle may not differ from those exerted by synthetic hormones 
contained within contraceptives. Collectively, these studies confirm that MSNA 
recruitment is affected by hormone phase, but in a reflex-specific manner. 
  
122 
 
5.4 References 
Abbott DH, Dumesic DA, & Franks S (2002). Developmental origin of polycystic ovary 
syndrome - a hypothesis. J Endocrinol 174, 1-5. 
Carter JR, Klein JC, & Schwartz CE (2009a). Effects of oral contraceptives on 
sympathetic nerve activity during orthostatic stress in young, healthy women. Am J 
Physiol Regul Integr Comp Physiol 298, R9-R14. 
Carter JR, Lawrence JE, & Klein JC (2009b). Menstrual cycle alters sympathetic neural 
responses to orthostatic stress in young, eumenorrheic women. Am J Physiol Endocrinol 
Metab 297, E85-E91. 
Day DS, Gozansky WS, Bell C, & Kohrt WM (2011). Acute sex hormone suppression 
reduces skeletal muscle sympathetic nerve activity. Clin Auton Res 21, 339-345. 
Eaker ED, Packard B, & Thom TJ (1989). Epidemiology and risk factors for coronary 
heart disease in women. Cardiovasc Clin 19, 129-145. 
Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, & Ghazzi MN (2006). 
Prevalence and predictors of the metabolic syndrome in women with polycystic ovary 
syndrome. J Clin Endocrinol Metab 91, 48-53. 
Ettinger SM, Silber DH, Gray KS, Smith MB, Yang QX, Kunselman AR, & Sinoway LI 
(1998). Effects of the ovarian cycle on sympathetic neural outflow during static exercise. 
J Appl Physiol 85, 2075-2081. 
Fu Q, Okazaki K, Shibata S, Shook RP, VanGunday TB, Galbreath MM, Reelick MF, & 
Levine BD (2009). Menstrual cycle effects on sympathetic neural responses to upright 
tilt. The Journal of Physiology 587, 2019-2031. 
123 
 
Hart EC, Charkoudian N, Wallin BG, Curry TB, Eisenach J, & Joyner MJ (2011). Sex 
and ageing differences in resting arterial pressure regulation: the role of the beta-
adrenergic receptors. J Physiol 589, 5285-5297. 
Hart EC, Charkoudian N, Wallin BG, Curry TB, Eisenach JH, & Joyner MJ (2009). Sex 
differences in sympathetic neural-hemodynamic balance: Implications for human blood 
pressure regulation. Hypertension 53, 571-576. 
Jones PP, Davy KP, & Seals DR (1999). Influence of gender on the sympathetic neural 
adjustments to alterations in systemic oxygen levels in humans. Clin Physiol 19, 153-160. 
Kienbaum P, Karlssonn T, Sverrisdottir YB, Elam M, & Wallin BG (2001). Two sites for 
modulation of human sympathetic activity by arterial baroreceptors? J Physiol 531, 861-
869. 
Malpas SC (1995). A new model for the generation of sympathetic nerve activity. Clin 
Exp Pharmacol Physiol 22, 11-15. 
Matsukawa T, Sugiyama Y, Watanabe T, Kobayashi F, & Mano T (1998). Gender 
difference in age-related changes in muscle sympathetic nerve activity in healthy 
subjects. Am J Physiol Regul Integr Comp Physiol 275, R1600-R1604. 
Meyer ML, Malek AM, Wild RA, Korytkowski MT, & Talbott EO (2012). Carotid artery 
intima-media thickness in polycystic ovary syndrome: a systematic review and meta-
analysis. Hum Reprod Update 18, 112-126. 
Middlekauff HR, Park J, & Gornbein JA (2012). Lack of effect of ovarian cycle and oral 
contraceptives on baroreceptor and nonbaroreceptor control of sympathetic nerve activity 
in healthy women. Am J Physiol Heart Circ Physiol 302, H2560-H2566. 
124 
 
Miner JA, Martini ER, Smith MM, Brunt VE, Kaplan PF, Halliwill JR, & Minson CT 
(2011). Short-term oral progesterone administration antagonizes the effect of transdermal 
estradiol on endothelium-dependent vasodilation in young healthy women. Am J Physiol 
Heart Circ Physiol 301, H1716-H1722. 
Minson CT, Halliwill JR, Young TM, & Joyner MJ (2000a). Influence of the Menstrual 
Cycle on Sympathetic Activity, Baroreflex Sensitivity, and Vascular Transduction in 
Young Women. Circulation 101, 862-868. 
Minson CT, Halliwill JR, Young TM, & Joyner MJ (2000b). Sympathetic Activity and 
Baroreflex Sensitivity in Young Women Taking Oral Contraceptives. Circulation 102, 
1473-1476. 
Narkiewicz K, Phillips BG, Kato M, Hering D, Bieniaszewski L, & Somers VK (2005). 
Gender-Selective Interaction Between Aging, Blood Pressure, and Sympathetic Nerve 
Activity. Hypertension 45, 522-525. 
Ng AV, Callister R, Johnson DG, & Seals DR (1993). Age and gender influence muscle 
sympathetic nerve activity at rest in healthy humans. Hypertension 21, 498-503. 
Rosano GM, Vitale C, Marazzi G, & Volterrani M (2007). Menopause and 
cardiovascular disease: the evidence. Climacteric 10 Suppl 1, 19-24. 
Rosenthal T & Oparil S (2000). Hypertension in women. J Hum Hypertens 14, 691-704. 
Schlaich MP, Straznicky N, Grima M, Ika-Sari C, Dawood T, Mahfoud F, Lambert E, 
Chopra R, Socratous F, Hennebry S, Eikelis N, Bohm M, Krum H, Lambert G, Esler 
MD, & Sobotka PA (2011). Renal denervation: a potential new treatment modality for 
polycystic ovary syndrome? J Hypertens 29, 991-996. 
125 
 
Sudhir K, Jennings GL, Funder JW, & Komesaroff PA (1996). Estrogen enhances basal 
nitric oxide release in the forearm vasculature in perimenopausal women. Hypertension 
28, 330-334. 
Sverrisdottir YB, Mogren T, Kataoka J, Janson PO, & Stener-Victorin E (2008). Is 
polycystic ovary syndrome associated with high sympathetic nerve activity and size at 
birth? Am J Physiol Endocrinol Metab 294, E576-E581. 
Young T, Palta M, Dempsey J, Skatrud J, Weber S, & Badr S (1993). The occurrence of 
sleep-disordered breathing among middle-aged adults. N Engl J Med 328, 1230-1235.  
126 
 
 
 
 
 
 
 
 
Appendix A: Ethics Approval 
  
127 
 
 
 
  
128 
 
 
  
129 
 
 
 
 
 
 
 
 
Appendix B: Letters of Information 
 
  
130 
 
 
 
 
 
 
LETTER OF INFORMATION 
 
Sex-Specific Hormone Levels and Reflex Sympathoexcitation 
 
Principal Investigator:   Dr. J. Kevin Shoemaker 
 
Research Coordinator:   Charlotte W. Usselman, M.Sc. 
 
Sponsor:     Natural Sciences and Engineering Research Council of 
Canada 
 
 You are being invited to participate in a research study that will examine how 
male and female hormone levels influence the nervous system. Before agreeing to 
participate, please read this Letter of Information. If you would like more details 
regarding something mentioned in this letter, or information not included here, please 
ask. Take time to read this carefully and to understand the following information. You 
will receive a copy of this letter to keep as your own. A total of 30 people will participate 
in this study.  
 
Introduction 
 
 The nervous system plays an important role in controlling your heart rate and 
blood pressure. Interestingly, it appears that the nervous system is influenced by the sex 
hormones which circulate in your body (for example, estrogen and testosterone). To 
better understand how hormones influence the nervous system, this study has two 
purposes. The first purpose is to compare the nervous systems of men and women. The 
second purpose is to compare the nervous systems of women at two different phases of 
the menstrual cycle.  
 
 The study will take place on three separate days. The first day will be a 
familiarization session, lasting approximately 45 minutes. On this day the procedures will 
be explained and practiced so that you are comfortable with all aspects of the study. The 
remaining two sessions will each last approximately 3 hours. If you agree to participate, 
on each day you will be required to come to the laboratory approximately three hours 
following a light meal, and after having avoided exercise, alcohol, smoking, nicorette 
gum, recreational drugs, coffee, tea, soft drinks and chocolate for at least 12 hours. On 
arrival at the laboratory you will be asked questions about the medical history of you and 
your family.  
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Participant Inclusion/Exclusion Criteria 
 
 You will not be included in the study if you are under 18 or over 35 years of age. 
You will not be included in the study if you are, or think you could be, pregnant. In 
addition, you will not be included in the study if you are a smoker. Also, you will not be 
included in the study if you have any of the following: a resting blood pressure above 
139/85 or below 100/55, respiratory disorders (e.g. asthma) or illnesses (e.g. bronchitis), 
cardiovascular disorders (e.g. Raynaud’s disease), metabolic diseases (e.g. diabetes), or a 
history of fainting.  
 
Measurements 
 
 If you agree to participate in this study, testing will be conducted at the 
Neurovascular Research Laboratory, Room 3110 Thames Hall at The University of 
Western Ontario. The testing procedure will involve the measurement of several 
cardiovascular variables during the 3-hour testing period: 
 
1. Small adhesive electrodes will be placed on your chest to record the electrical 
heart rate tracing (electrocardiogram; ECG).  
 
2. A small cuff will be placed around one finger and a blood pressure cuff will be 
placed around the upper portion of the same arm. These cuffs are used to measure 
your blood pressure. When activated, the finger cuff will inflate with air and you 
should feel a pulsating sensation on your finger.  
 
3. An elastic strap will be placed around your chest to monitor changes in breathing 
rate and depth.  
 
4. Small probes will be clipped on to one earlobe and one of your toes. These probes 
emit a light that passes easily through the earlobe and toe and lets us measure the 
amount of oxygen in your blood. 
 
5. To examine your blood vessels, ultrasound probes will be placed on top of the 
skin at your elbow and at the base of your neck in order to measure the size of 
your vessels and the amount of blood flowing through them. These probes are 
similar to those used on pregnant women for imaging of an unborn child.   
 
6. You are being asked to undergo a procedure called “microneurography”. This 
procedure has two phases. First, the position of a nerve that runs very close to 
your skin just on the outside of the knee will be located by touch. Second, a thin 
tungsten electrode (similar to an acupuncture needle, about the size of a large 
human hair) will be inserted through the intact skin and positioned just under the 
skin about 2-3 cm from the nerve site. This will be followed by the placement of a 
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second tungsten electrode through the intact skin into this nerve (called the 
peroneal nerve). This second electrode will be manipulated gently until the 
appropriate recording site is found. The microelectrodes are sterilized before use 
and the area of skin around the knee is cleansed with alcohol before and after the 
procedure.  
 
7. You will lie down on a table, with your legs and hips sealed inside a box that is 
connected to a vacuum source. This box is designed to produce suction (negative 
pressure) around your lower body. This mimics the effects of standing in terms of 
cardiovascular and nervous system responses. You will undergo 1-3 levels of 
lower body suction, starting at -60 mmHg (this level is comparable to standing 
upright) up to a maximum of -80 mmHg, for no longer than 2 minutes at a time.  
 
8. During a portion of the experiment you will be given a mouthpiece to place in 
your mouth, which allows you to breathe normally. This mouthpiece will be 
attached to a valve that opens to either room air or a bag. At rest you will breathe 
room air. During one of the protocols the valve will be turned so that you will be 
breathing in and out of the bag. By breathing in and out of the bag we will be 
altering the amounts of oxygen and carbon dioxide in your blood. This will cause 
your rate and depth of breathing to increase, and will last for approximately 5 
minutes. Immediately following this “rebreathing”, we will also ask you to hold 
your breath for “as long as possible”; in most individuals this will not be longer 
than 30 seconds.  
 
Procedures 
 
 Each day of testing will last approximately two hours, and will be carried out 
according to the order and timing illustrated in the following diagram. The procedures 
and measures used on each day will be identical.  
 
 
1. We will begin by setting up the devices listed above in the “Measurements” 
section. This will take approximately 20 minutes. During this period you will 
simply be required to lie down and rest on a padded table.  
2. Next, a small plastic tube will be inserted into a vein in your elbow by a registered 
nurse. This tube will be connected to a device that measures blood pressure in that 
vein. Also, blood will be taken from this tube at one time during the test. The total 
amount of blood withdrawn will not exceed 10 mL (2 teaspoons). The blood 
samples will be measured for sex hormones as well as hormones that regulate 
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blood pressure and blood vessels (e.g. estrogen, testosterone, progesterone, c-
reactive protein).  
3. Following the blood draw, we will begin the process of locating a recording site 
in your peroneal nerve through microneurography. While 1 hour has been allotted 
for the process, this is a maximum. It is possible that a suitable recording site 
could be found within the 1 hour time frame.  
4. You will be asked to lay quietly and rest for a 10 minute “baseline” period. 
5. Breathing Task: 
1. This task will be performed with the mouthpiece in your mouth (see 
“Measurements”, item 8). To begin, the valve will be turned from room air to the 
bag, and you will be asked to breathe in and out of the bag. You will continue to 
breathe in and out of the bag until the gases in the bag change a desired amount. 
At this point you will be asked to take in one more breath, and then hold your 
breath for as long as possible. When you cannot hold your breath any longer, you 
will exhale, then take 2 final breaths in and out of the bag. The valve will then be 
turned back to room air.  
6. You will be asked to lay quietly and rest for at least 5 minutes.  
7. Lower Body Suction Task: 
While lying quietly on your back, lower body suction of -60 mmHg will be 
applied for a duration of 2 minutes, after which you will be allowed at least 2 
minutes to recover. You will be asked to brace yourself with one leg (the opposite 
leg used for microneurography) during suction. Lower body suction will then be 
increased in 10 mmHg increments up to -80 mmHg, with at least 2 minutes of rest 
between each level.  
 As indicated above, the entire procedure will take approximately 3 hours to 
complete on each test day. Upon completion of the experiment you will rise slowly from 
the table into a seated position. After approximately 30-60 seconds of sitting you will be 
permitted to stand beside the bed and move about the lab when you feel comfortable to 
do so.  
Risks 
ECG 
The adhesive on the electrodes used to measure your heart rate may cause a small rash to 
develop under the electrode. However, this rash should disappear in a day or two.  
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Blood Pressure Cuff 
There are no known risks of using the finger cuff methods (Finometer) of examining 
arterial blood pressure. With the finger cuff the finger tip may turn a little blue and feel 
numb during the prolonged test sessions but this resolves immediately when the cuff is 
removed. Standard arm cuff blood pressure measures of arterial pressure will also be 
obtained periodically, a method that has no known risks. 
 
Ultrasound 
There are no known harmful effects with standard diagnostic ultrasound techniques. 
 
Blood Oxygen Saturation 
There are no known risks associated with the use of this device. 
 
Blood Draw 
There is a small risk of bruising or infection when collecting blood from your vein. Some 
participants may experience mild pain and discomfort and some may feel nauseated or 
dizzy when blood is taken.  
 
Microneurography 
Insertion of the microneurography electrodes within the nerve may cause some “pins and 
needles” or muscle cramping sensations. These sensations disappear immediately by 
changing electrode position. There will be no sensations when the needle is in the correct 
position. There is small chance of these sensations occurring around the area of needle 
insertion immediately following the study and a less than 1% chance of these sensations 
persisting longer than one day. Other extremely rare reactions include infection and/or 
bleeding when the electrode is removed. Once in place there is no discomfort from the 
electrodes. You will be advised to partake only in normal day-to-day activities and 
abstain from aggressive physical effort or exercise for 24 hours after the study, such as 
lifting weights, running or competitive sports. 
 
Lower Body Suction 
During lower body suction you may feel faint or dizzy. These symptoms may lead to 
actual fainting. To ensure this does not happen, we will ask you to inform us if you feel 
any of the following symptoms: nausea, light-headedness, tunnel vision, blurry vision, 
excessive heat and/or sweating. These symptoms are alleviated quickly by turning off the 
lower body suction. You may stop the test at any time. Also, we will be monitoring you 
throughout the experiment to ensure that you are okay and we will stop the test if we feel 
that it is necessary. 
 
Breathing Protocol 
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The rebreathing protocol may last for a duration of up to 5 minutes. Subsequent breath-
holding may last for a duration of up to 30 seconds. The decreasing amount of oxygen 
and increasing amount of carbon dioxide may give you a sensation of breathlessness. 
This sensation will go away immediately when you are switched to breathe room air. In 
the case that you become uncomfortable due to the breathless sensation, you will be 
returned immediately to air breathing which will alleviate the sensation. The increase in 
carbon dioxide in the air you breathe during rebreathing may cause a slight headache to 
occur, which will be reversed immediately upon returning to breathing room air. 
Decreases in oxygen much greater than used here carry the risk of dizziness or fainting. 
To date, the reduction in blood oxygen as used in this study has been conducted on 83 
individuals. In one of these participants, the study was stopped early because the 
individual became dizzy. Given the limited number of people that this procedure has been 
conducted on, the exact level of risk has not yet been determined. To ensure your safety 
during these studies your blood oxygen content will be monitored continuously and we 
will return you to breathing room air if the amount of oxygen in your blood decreases 
below 80%. Also, your heart rate and blood pressure will be monitored continuously. The 
study will be stopped if your heart rate or blood pressure fall to levels below normal for 
more than 10 heart beats. You may stop the test at any time. 
 
Staying Still 
During the experiment, you will have to remain still in a lying down position for 2 hours. 
You may develop a sore back in the middle of the experiment. These sensations will 
diminish very quickly when you sit up from the bed after the experiment.  
 
 
In the event that you suffer injury as a result of participating in this research no 
compensation will be provided for you by The University of Western Ontario, or the 
Researchers. You still have all your legal rights. Nothing said here about treatment or 
compensation in any way alters your right to recover damages.  
 
Alternatives to Participating 
 
You may choose not to participate in this study. 
 
Benefits to You if You Take Part in the Study 
 
There are no direct benefits to you as a result of participating in this study. 
 
Voluntary Participation 
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You are encouraged to ask questions regarding the purpose of this study and the 
outcome of your testing. Participation in this study is voluntary. You may refuse to 
participate, refuse to answer any questions, or withdraw from the study at any time with 
no effect on your academic or employment status. We ask that you do not get involved 
with any other study while you are involved in this study. However, participation in this 
study will not stop you from being involved in future studies. You do not waive any legal 
rights by signing the consent form.  
 
Confidentiality 
 
 All information that you provide will be kept strictly confidential. No information 
that could reveal your identity will be released to anyone unless disclosure is required 
legally. All of the information collected for this study will be stored in a locked filing 
cabinet or a password-protected computer that will only be accessible to the research 
team. To further protect your confidentiality, your name will be replaced with a subject 
ID number on all documents. 
 
 Representatives of The University of Western Ontario Health Sciences Research 
Ethics Board may contact you or require access to your study-related records or may 
follow up with you to monitor the conduct of the research. 
 
Compensation 
 
 You will be reimbursed for travel and/or parking expenses (not exceeding $20 per 
visit). 
 
Publication of Results 
  
Published results from this study will not identify you by name. New findings 
from this study may be forwarded to each interested participant upon request. You may 
keep a copy of this letter of information.  
 
Contact Persons 
 
If you have any questions regarding this study, please feel free to contact: 
 
 Dr. Kevin Shoemaker 
 (519) 661-2111 ext. 85759 
 Room 3110 Thames Hall 
 The University of Western Ontario 
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If you have any questions about your rights as a participant or about the conduct 
of the study you may contact The University of Western Ontario Office of Research 
Ethics, 519-661-3036 or email ethics@uwo.ca. 
 
 
 
 
  
 
 
 
LETTER OF INFORMED CONSENT 
 
Sex-Specific Hormone Levels and Reflex Sympathoexcitation 
 
Principal Investigator:   Dr. J. Kevin Shoemaker 
 
Research Coordinator:   Charlotte W. Usselman, M.Sc. 
 
I have read the Letter of Information, have had the nature of the study explained to 
me, and I agree to participate. All questions have been answered to my satisfaction. 
 
_______________________________ _______________________________ 
Name of participant (Please print)  Name of person obtaining consent 
 
 
 
_______________________________ _______________________________ 
Signature of participant   Signature of person obtaining consent 
 
 
 
_____________________    _____________________ 
Date       Date 
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LETTER OF INFORMATION 
 
Sex-Specific Hormone Levels and Reflex Sympathoinhibition 
 
Principal Investigator:   Dr. J. Kevin Shoemaker 
 
Research Coordinator:   Charlotte W. Usselman, M.Sc. 
 
Sponsor:     Natural Sciences and Engineering Research Council of 
Canada 
 
 You are being invited to participate in a research study that will examine how 
male and female hormone levels influence the nervous system. Before agreeing to 
participate, please read this Letter of Information. If you would like more details 
regarding something mentioned in this letter, or information not included here, please 
ask. Take time to read this carefully and to understand the following information. You 
will receive a copy of this letter to keep as your own. A total of 50 people will participate 
in this study. 
 
Introduction 
 
 The nervous system plays an important role in controlling your heart rate and 
blood pressure. Interestingly, it appears that the nervous system is influenced by the sex 
hormones which circulate in your body (for example, estrogen and testosterone). To 
better understand how hormones influence the nervous system, this study has two 
purposes. The first purpose is to compare the nervous systems of men and women. The 
second purpose is to compare the nervous systems of women at two different phases of 
the menstrual cycle.  
 
 The study will take place on three separate days. The first day will be a 
familiarization session, lasting approximately 45 minutes. On this day the procedures will 
be explained and practiced so that you are comfortable with all aspects of the study. The 
remaining two sessions will each last approximately 3 hours. If you agree to participate, 
on each day you will be required to come to the laboratory approximately three hours 
following a light meal, and after having avoided exercise, alcohol, smoking, nicorette 
gum, recreational drugs, coffee, tea, soft drinks and chocolate for at least 12 hours. On 
arrival at the laboratory you will be asked questions about the medical history of you and 
your family.  
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Participant Inclusion/Exclusion Criteria 
 
 You will not be included in the study if you are under 18 or over 35 years of age. 
You will not be included in the study if you are, or think you could be, pregnant. In 
addition, you will not be included in the study if you are a smoker. Also, you will not be 
included in the study if you have any of the following: a resting blood pressure above 
139/85 or below 100/55, respiratory disorders (e.g. asthma) or illnesses (e.g. bronchitis), 
cardiovascular disorders (e.g. Raynaud’s disease), metabolic diseases (e.g. diabetes), or a 
history of fainting.  
 
Measurements 
 
 If you agree to participate in this study, testing will be conducted at the 
Neurovascular Research Laboratory, Room 3110 Thames Hall at The University of 
Western Ontario. The testing procedure will involve the measurement of several 
cardiovascular variables: 
 
1. Small adhesive electrodes will be placed on your chest to record the electrical 
heart rate tracing (electrocardiogram; ECG).  
 
2. A small cuff will be placed around one finger and a blood pressure cuff will be 
placed around the upper portion of the same arm. These cuffs are used to measure 
your blood pressure. When activated, the finger cuff will inflate with air and you 
should feel a pulsating sensation on your finger.  
 
3. An elastic strap will be placed around your chest to monitor changes in breathing 
rate and depth. 
 
4. A small probe will be clipped on one of your toes. This probe emits a light that 
passes through the toe and lets us measure the amount of oxygen in your blood.  
 
5. To examine your blood vessels, ultrasound probes will be placed on top of the 
skin at your elbow and at the base of your neck in order to measure the size of 
your vessels and the amount of blood flowing through them. These probes are 
similar to those used on pregnant women for imaging of an unborn child.   
 
6. You are being asked to undergo a procedure called “microneurography”. This 
procedure has two phases. First, the position of a nerve that runs very close to 
your skin just on the outside of the knee will be located by touch. Second, a thin 
tungsten electrode (similar to an acupuncture needle, about the size of a large 
human hair) will be inserted through the intact skin and positioned just under the 
skin about 2-3 cm from the nerve site. This will be followed by the placement of a 
second tungsten electrode through the intact skin into this nerve (called the 
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peroneal nerve). This second electrode will be manipulated gently until the 
appropriate recording site is found. The microelectrodes are sterilized before use 
and the area of skin around the knee is cleansed with alcohol before and after the 
procedure.  
 
7. You will lie down on a table which can be tilted automatically. You will be tilted 
to a slight head-down position (6° from the horizontal plane) for 1 minute periods. 
This will cause a small increase in the amount of blood in your chest, and a small 
decrease in the amount of blood contained in your legs.  
 
8. You will be asked to perform a very mild handgrip exercise task. During this task 
you will squeeze a small air-filled bag at a level that requires 5% of your maximal 
voluntary strength (i.e. the hardest you can possibly squeeze the bag) for 1 minute 
periods.  
 
9. You will be asked to breathe at a rate of 15 breaths per second. A metronome set 
to the same rate will assist you in maintaining this pattern.  
 
10. During (6) and (7), you will be lying down with your legs and hips sealed inside a 
box that is connected to a vacuum source. This box is designed to produce suction 
(negative pressure) around your lower body. This mimics the effects of standing 
in terms of cardiovascular and nervous system responses. During two of the tilt 
tests, and two of the handgrips, the vacuum source will be turned on to a lower 
body suction level of -30 mmHg. This is a mild to moderate level of suction, less 
stressful than standing up. 
 
Procedures 
 
 Each day of testing will last approximately two hours, and will be carried out 
according to the order and timing illustrated in the following diagram. The three 
experimental protocols (head-down tilt, handgrip, and paced breathing) are illustrated as 
“A”, “B”, and “C” because you will determine the order in which they are carried out by 
rolling a dice. The order of protocols determined on the first day of testing will be 
repeated on the second day of testing.   
 
 
1. We will begin by setting up the devices listed above in the “Measurements” 
section. This will take approximately 20 minutes. During this period you will 
simply be required to lie down and rest on a padded table.  
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2. Next, a small plastic tube will be inserted into a vein in your elbow by a registered 
nurse. This tube will be connected to a device that measures blood pressure in that 
vein. Also, blood will be taken from this tube at one time during the test. The total 
amount of blood withdrawn will not exceed 10 mL (2 teaspoons). The blood 
samples will be measured for sex hormones as well as hormones that regulate 
blood pressure and blood vessels (e.g. estrogen, testosterone, progesterone, c-
reactive protein). 
3. Following the blood draw, we will begin the process of locating a recording site 
in your peroneal nerve through microneurography. While 1 hour has been allotted 
for the process, this is a maximum. It is possible that a suitable recording site 
could be found within the 1 hour time frame.  
4. You will be asked to lay quietly and rest for a 10 minute “baseline” period. 
5. Head-Down Tilt Task: 
To begin, you will lie horizontally (zero degrees of tilt) on the table with your 
lower body sealed inside a box (see “Measurements”, item 8). In total, you will be 
tilted to a head-down position (6 degrees of tilt) 4 times. Two of the tilts will be 
completed without lower body suction, and will last 2 minutes each. In the 
remainder of the trials, we will first turn on lower body suction to -30 mmHg for 
2 minutes. At this, you will be tilted head-down. That is, you will be tilted while 
suction is applied to your lower body. You will then be returned to the horizontal 
position for a final 2 minutes of lower body suction. This will be followed by 2 
minutes of rest.  
6. You will be asked to lay quietly and rest for at least 5 minutes. 
  
7. Handgrip Task: 
Before beginning the handgrip task, you will be asked to squeeze a small air-filled 
bag as hard as you can. This represents handgrip exercise at 100%. For the rest of 
the task, you will squeeze the bag at 5% of your maximal strength for 1 minute at 
a time. You will be able to see a screen that tells you how hard you are squeezing. 
You will complete 4 trials in total. Similar to the tilt task, you will perform 2 trials 
consisting of handgrip alone, and the other two trials will consist of a combination 
of lower body suction and handgrip. Each handgrip trial will be followed by 1 
minute of quiet rest. 
8. Paced Breathing Task: 
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During this task, you will be asked to breathe in time with a metronome, which 
will be set to 15 breaths per minute. That is, you will breathe in and out every 4 
seconds for a total of 5 minutes.  
  
As indicated above, the entire procedure will take approximately 3 hours to 
complete on each test day. Upon completion of the experiment you will rise slowly from 
the table into a seated position. After approximately 30-60 seconds of sitting you will be 
permitted to stand beside the bed and move about the lab when you feel comfortable to 
do so.  
Risks 
ECG 
The adhesive on the electrodes used to measure your heart rate may cause a small rash to 
develop under the electrode. However, this rash should disappear in a day or two.  
 
Blood Pressure Cuff 
There are no known risks of using the finger cuff methods (Finometer) of examining 
arterial blood pressure. With the finger cuff the finger tip may turn a little blue and feel 
numb during the prolonged test sessions but this resolves immediately when the cuff is 
removed. Standard arm cuff blood pressure measures of arterial pressure will also be 
obtained periodically, a method that has no known risks. 
 
Ultrasound 
There are no known harmful effects with standard diagnostic ultrasound techniques. 
 
Blood Oxygen Saturation 
There are no known risks associated with the use of this device. 
 
Blood Draw 
There is a small risk of bruising or infection when collecting blood from your vein. Some 
participants may experience mild pain and discomfort and some may feel nauseated or 
dizzy when blood is taken.  
 
Head-Down Tilt 
There are no known risks associated with the mild level of head-down tilt used in this 
protocol. Head-down tilt is commonly used in physiotherapy. 
 
Handgrip 
There are no known risks associated with the low intensity of handgrip exercise used in 
this protocol.  
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Microneurography 
Insertion of the microneurography electrodes within the nerve may cause some “pins and 
needles” or muscle cramping sensations. These sensations disappear immediately by 
changing electrode position. There will be no sensations when the needle is in the correct 
position. There is small chance of these sensations occurring around the area of needle 
insertion immediately following the study and a less than 1% chance of these sensations 
persisting longer than one day. Other extremely rare reactions include infection and/or 
bleeding when the electrode is removed. Once in place there is no discomfort from the 
electrodes. You will be advised to partake only in normal day-to-day activities and 
abstain from aggressive physical effort or exercise for 24 hours after the study, such as 
lifting weights, running or competitive sports. 
 
Lower Body Suction 
During lower body suction you may feel faint or dizzy. These symptoms may lead to 
actual fainting. To ensure this does not happen, we will ask you to inform us if you feel 
any of the following symptoms: nausea, light-headedness, tunnel vision, blurry vision, 
excessive heat and/or sweating. These symptoms are alleviated quickly by turning off the 
lower body suction. You may stop the test at any time. Also, we will be monitoring you 
throughout the experiment to ensure that you are okay and we will stop the test if we feel 
that it is necessary. 
 
Paced Breathing 
There are no known risks associated with paced breathing. This technique is commonly 
used during meditation. 
 
Staying Still 
During the experiment, you will have to remain still in a lying down position for 2 hours. 
You may develop a sore back in the middle of the experiment. These sensations will 
diminish very quickly when you sit up from the bed after the experiment.  
 
 
In the event that you suffer injury as a result of participating in this research no 
compensation will be provided for you by The University of Western Ontario, or the 
Researchers. You still have all your legal rights. Nothing said here about treatment or 
compensation in any way alters your right to recover damages.  
 
Alternatives to Participating 
 
You may choose not to participate in this study. 
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Benefits to You if You Take Part in the Study 
 
There are no direct benefits to you as a result of participating in this study. 
 
Voluntary Participation 
 
You are encouraged to ask questions regarding the purpose of this study and the 
outcome of your testing. Participation in this study is voluntary. You may refuse to 
participate, refuse to answer any questions, or withdraw from the study at any time with 
no effect on your academic or employment status. We ask that you do not get involved 
with any other study while you are involved in this study. However, participation in this 
study will not stop you from being involved in future studies. You do not waive any legal 
rights by signing the consent form.  
 
Confidentiality 
 
 All information that you provide will be kept strictly confidential. No information 
that could reveal your identity will be released to anyone unless disclosure is required 
legally. All of the information collected for this study will be stored in a locked filing 
cabinet or a password-protected computer that will only be accessible to the research 
team. To further protect your confidentiality, your name will be replaced with a subject 
ID number on all documents. 
 
 Representatives of The University of Western Ontario Health Sciences Research 
Ethics Board may contact you or require access to your study-related records or may 
follow up with you to monitor the conduct of the research. 
 
Compensation 
 
 You will be reimbursed for travel and/or parking expenses (not exceeding $20 per 
visit). 
 
Publication of Results 
  
Published results from this study will not identify you by name. New findings 
from this study may be forwarded to each interested participant upon request. You may 
keep a copy of this letter of information.  
 
 
145 
 
Contact Persons 
 
If you have any questions regarding this study, please feel free to contact: 
 
 Dr. Kevin Shoemaker 
 (519) 661-2111 ext. 85759 
 Room 3110 Thames Hall 
 The University of Western Ontario 
 
If you have any questions about your rights as a participant or about the conduct 
of the study you may contact The University of Western Ontario Office of Research 
Ethics, 519-661-3036 or email ethics@uwo.ca. 
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LETTER OF INFORMED CONSENT 
 
Sex-Specific Hormone Levels and Reflex Sympathoinhibition 
 
Principal Investigator:   Dr. J. Kevin Shoemaker 
 
Research Coordinator:   Charlotte W. Usselman, M.Sc. 
 
I have read the Letter of Information, have had the nature of the study explained to 
me, and I agree to participate. All questions have been answered to my satisfaction. 
 
_______________________________ _______________________________ 
Name of participant (Please print)  Name of person obtaining consent 
 
 
 
_______________________________ _______________________________ 
Signature of participant   Signature of person obtaining consent 
 
 
 
_____________________    _____________________ 
Date       Date 
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Terms and Conditions for Permissions 
Nature Publishing Group hereby grants you a non-exclusive license to reproduce 
this material for 
this purpose, and for no other use,subject to the conditions below: 
1. NPG warrants that it has, to the best of its knowledge, the rights to license reuse of 
this material. However, you should ensure that the material you are requesting is 
original to Nature Publishing Group and does not carry the copyright of another entity 
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UK: [JOURNAL NAME] (reference citation), copyright (year of publication) 
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4. The Materials and all of the intellectual property rights therein shall at all times 
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the unrestricted use, distribution, reproduction, adaptation and commercial 
exploitation of the article in any medium. No permission is required to use the 
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NoDerivatives (CC BY-NC-ND). The CC BY-NC-ND is more restrictive than the 
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Copyright notices and disclaimers must not be deleted. 
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